Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
HarvardTrials will no longer be available as of June 7. You can search ClinicalTrials.gov directly for Harvard-sponsored studies. If you have questions, please email us.
Check out the new look and feel of Harvard Catalyst Profiles! Learn more on our About and Help pages.

Soldano Ferrone, Ph.D., M.D.

Title
Institution
Department
Address
Phone

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R03CA175957 (FERRONE, SOLDANO) Jul 1, 2014 - Jun 30, 2016
    NIH/NCI
    HSP based combinatorial immunotherapy in triple negative breast cancer
    Role: Principal Investigator
  2. R21CA173120 (BUCHSBAUM, DONALD J.) Jan 1, 2014 - Dec 31, 2015
    NIH/NCI
    Therapy of pancreatic cancer with 212Pb-labeled B7-H3 specific Ab and LDE225
    Role: Co-Principal Investigator
  3. R21CA164756 (FERRONE, SOLDANO) Sep 11, 2013 - Aug 31, 2015
    NIH/NCI
    Grp94 targeted therapy for pancreatic ductal adenocarcinoma
    Role: Principal Investigator
  4. R01CA138188 (FERRONE, SOLDANO) Sep 19, 2008 - Jul 31, 2014
    NIH/NCI
    Combinatorial targeting of melanoma initiating cells
    Role: Principal Investigator
  5. R01CA110249 (FERRONE, SOLDANO) Aug 1, 2006 - Apr 30, 2014
    NIH/NCI
    Antigen processing and HLA-peptide complexes in head and neck cancer
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. Corrigendum to '212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models' [Nucl Med Biol 58 (2018) 67-73]. Nucl Med Biol. 2018 Apr 25. PMID: 29705525.
    View in: PubMed
  2. Eng MS, Kaur J, Prasmickaite L, Engesæter BØ, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Mælandsmo GM, Høgset A, Ferrone S, Selbo PK. Enhanced targeting of triple-negative breast carcinoma and malignant melanoma by photochemical internalization of CSPG4-targeting immunotoxins. Photochem Photobiol Sci. 2018 Mar 22. PMID: 29565434.
    View in: PubMed
  3. Kasten BB, Oliver PG, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci. 2018 Mar 21; 19(4). PMID: 29561763.
    View in: PubMed
  4. Pellegatta S, Savoldo B, Di Ianni N, Corbetta C, Chen Y, Patané M, Sun C, Pollo B, Ferrone S, DiMeco F, Finocchiaro G, Dotti G. Constitutive and TNFa-inducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. Sci Transl Med. 2018 Feb 28; 10(430). PMID: 29491184.
    View in: PubMed
  5. Cai L, Michelakos T, Yamada T, Fan S, Wang X, Schwab JH, Ferrone CR, Ferrone S. Defective HLA class I antigen processing machinery in cancer. Cancer Immunol Immunother. 2018 Feb 27. PMID: 29487978.
    View in: PubMed
  6. Sharma P, Ludwig S, Muller L, Hong CS, Kirkwood JM, Ferrone S, Whiteside TL. Immunoaffinity-based isolation of melanoma cell-derived exosomes from plasma of patients with melanoma. J Extracell Vesicles. 2018; 7(1):1435138. PMID: 29511460.
    View in: PubMed
  7. Marra A, Ferrone CR, Fusciello C, Scognamiglio G, Ferrone S, Pepe S, Perri F, Sabbatino F. Translational Research in Cutaneous Melanoma: New Therapeutic Perspectives. Anticancer Agents Med Chem. 2018; 18(2):166-181. PMID: 29256359.
    View in: PubMed
  8. Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL. HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers. Oral Oncol. 2018 Feb; 77:92-97. PMID: 29362132.
    View in: PubMed
  9. Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, Zinn KR, Buchsbaum DJ. 212Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nucl Med Biol. 2018 Mar; 58:67-73. PMID: 29413459.
    View in: PubMed
  10. Wang X, Wang X, Gu J, Zhou M, He Z, Wang X, Ferrone S. Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP. Oncotarget. 2017 Dec 26; 8(69):113837-113846. PMID: 29371950.
    View in: PubMed
  11. Ascierto PA, Agarwala SS, Ciliberto G, Demaria S, Dummer R, Duong CPM, Ferrone S, Formenti SC, Garbe C, Halaban R, Khleif S, Luke JJ, Mir LM, Overwijk WW, Postow M, Puzanov I, Sondel P, Taube JM, Thor Straten P, Stroncek DF, Wargo JA, Zarour H, Thurin M. Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. J Transl Med. 2017 Nov 16; 15(1):236. PMID: 29145885.
    View in: PubMed
  12. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, Goldberg SB, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017 12; 7(12):1420-1435. PMID: 29025772.
    View in: PubMed
  13. Di Nicola M, Apetoh L, Bellone M, Colombo MP, Dotti G, Ferrone S, Muscolini M, Hiscott J, Anichini A, Pupa SM, Braud F, Del Vecchio M. Innovative Therapy, Monoclonal Antibodies and Beyond. Cytokine Growth Factor Rev. 2017 Dec; 38:1-9. PMID: 29029813.
    View in: PubMed
  14. Romoli MR, Di Gennaro P, Gerlini G, Sestini S, Brandani P, Ferrone S, Borgognoni L. High Antigen Processing Machinery component expression in Langerhans cells from melanoma patients' sentinel lymph nodes. Cell Immunol. 2017 Oct; 320:29-37. PMID: 28870403.
    View in: PubMed
  15. Cong J, Wang Y, Zhang X, Zhang N, Liu L, Soukup K, Michelakos T, Hong T, DeLeo A, Cai L, Sabbatino F, Ferrone S, Lee H, Levina V, Fuchs B, Tanabe K, Lillemoe K, Ferrone C, Wang X. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. Cancer Lett. 2017 11 28; 409:9-19. PMID: 28864067.
    View in: PubMed
  16. Wang X, Wang Y, Gu J, Zhou D, He Z, Wang X, Ferrone S. ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells. Sci Rep. 2017 Aug 29; 7(1):9687. PMID: 28852196.
    View in: PubMed
  17. Ravindranath MH, Cai J, Ferrone S, Claas FHJ, Selvan SR. The Humoral Theory of Transplantation. J Immunol Res. 2017; 2017:5935123. PMID: 28929124.
    View in: PubMed
  18. Ravindranath MH, Jucaud V, Ferrone S. Monitoring native HLA-I trimer specific antibodies in Luminex multiplex single antigen bead assay: Evaluation of beadsets from different manufacturers. J Immunol Methods. 2017 11; 450:73-80. PMID: 28782523.
    View in: PubMed
  19. Al-Sukaini A, Hornicek FJ, Peacock ZS, Kaban LB, Ferrone S, Schwab JH. Immune Surveillance Plays a Role in Locally Aggressive Giant Cell Lesions of Bone. Clin Orthop Relat Res. 2017 Dec; 475(12):3071-3081. PMID: 28725958.
    View in: PubMed
  20. Cai L, Michelakos T, Ferrone CR, Zhang L, Deshpande V, Shen Q, DeLeo A, Yamada T, Zhang G, Ferrone S, Wang X. Expression status of folate receptor alpha is a predictor of survival in pancreatic ductal adenocarcinoma. Oncotarget. 2017 Jun 06; 8(23):37646-37656. PMID: 28430580.
    View in: PubMed
  21. Yang KS, Im H, Hong S, Pergolini I, Del Castillo AF, Wang R, Clardy S, Huang CH, Pille C, Ferrone S, Yang R, Castro CM, Lee H, Del Castillo CF, Weissleder R. Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci Transl Med. 2017 05 24; 9(391). PMID: 28539469.
    View in: PubMed
  22. Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, Ugurel S, Schrama D, Becker JC. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017 May 23; 7(1):2290. PMID: 28536458.
    View in: PubMed
  23. Caratelli S, Sconocchia T, Arriga R, Coppola A, Lanzilli G, Lauro D, Venditti A, Del Principe MI, Buccisano F, Maurillo L, Ferrone S, Sconocchia G. FC? Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Front Immunol. 2017; 8:457. PMID: 28496440.
    View in: PubMed
  24. Maccalli C, Parmiani G, Ferrone S. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy. Immunol Invest. 2017 Apr; 46(3):221-238. PMID: 28287848.
    View in: PubMed
  25. Seliger B, Kloor M, Ferrone S. HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology. 2017; 6(2):e1171447. PMID: 28344859.
    View in: PubMed
  26. Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017 Apr; 47:23-30. PMID: 28104527.
    View in: PubMed
  27. Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313. PMID: 27846884.
    View in: PubMed
  28. Conteduca G, Fenoglio D, Parodi A, Battaglia F, Kalli F, Negrini S, Tardito S, Ferrera F, Salis A, Millo E, Pasquale G, Barra G, Damonte G, Indiveri F, Ferrone S, Filaci G. AIRE polymorphism, melanoma antigen-specific T cell immunity, and susceptibility to melanoma. Oncotarget. 2016 Sep 20; 7(38):60872-60884. PMID: 27563821.
    View in: PubMed
  29. Srivastava RM, Trivedi S, Concha-Benavente F, Gibson SP, Reeder C, Ferrone S, Ferris RL. CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer. Clin Cancer Res. 2017 Feb 01; 23(3):707-716. PMID: 27496866.
    View in: PubMed
  30. Concha-Benavente F, Srivastava R, Ferrone S, Ferris RL. Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells. Oral Oncol. 2016 07; 58:52-8. PMID: 27264839.
    View in: PubMed
  31. Trivedi S, Srivastava RM, Concha-Benavente F, Ferrone S, Garcia-Bates TM, Li J, Ferris RL. Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients. Clin Cancer Res. 2016 Nov 01; 22(21):5229-5237. PMID: 27217441.
    View in: PubMed
  32. Piras LA, Riccardo F, Iussich S, Maniscalco L, Gattino F, Martano M, Morello E, Lorda Mayayo S, Rolih V, Garavaglia F, De Maria R, Lardone E, Collivignarelli F, Mignacca D, Giacobino D, Ferrone S, Cavallo F, Buracco P. Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination. Vet Comp Oncol. 2017 Sep; 15(3):996-1013. PMID: 27146852.
    View in: PubMed
  33. Villani V, Mahadevan KK, Ligorio M, Fernández-Del Castillo C, Ting DT, Sabbatino F, Zhang I, Vangel M, Ferrone S, Warshaw AL, Lillemoe KD, Wargo J, Deshpande V, Ferrone CR. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors. Ann Surg Oncol. 2016 Dec; 23(Suppl 5):609-617. PMID: 27020585.
    View in: PubMed
  34. Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget. 2016 Feb 16; 7(7):7390-402. PMID: 26862729; PMCID: PMC4884926.
  35. Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, Ferrone CR, Ferrone S. Antitumor Activity of BRAF Inhibitor and IFNa Combination in BRAF-Mutant Melanoma. J Natl Cancer Inst. 2016 Jul; 108(7). PMID: 26851802; PMCID: PMC4948304 [Available on 07/01/17].
  36. Arriga R, Caratelli S, Coppola A, Spagnoli GC, Venditti A, Amadori S, Lanzilli G, Lauro D, Palomba P, Sconocchia T, Del Principe MI, Maurillo L, Buccisano F, Capuani B, Ferrone S, Sconocchia G. Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. Oncotarget. 2016 Jan 12; 7(2):2070-9. PMID: 26655503; PMCID: PMC4811516.
  37. Sottile R, Pangigadde PN, Tan T, Anichini A, Sabbatino F, Trecroci F, Favoino E, Orgiano L, Roberts J, Ferrone S, Kärre K, Colucci F, Carbone E. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors. Eur J Immunol. 2016 Feb; 46(2):409-19. PMID: 26564811; PMCID: PMC4832274.
  38. Schoenfeld AJ, Wang X, Wang Y, Hornicek FJ, Nielsen GP, Duan Z, Ferrone S, Schwab JH. CSPG4 as a prognostic biomarker in chordoma. Spine J. 2016 06; 16(6):722-7. PMID: 26689475.
    View in: PubMed
  39. Ascierto PA, Atkins M, Bifulco C, Botti G, Cochran A, Davies M, Demaria S, Dummer R, Ferrone S, Formenti S, Gajewski TF, Garbe C, Khleif S, Kiessling R, Lo R, Lorigan P, Arthur GM, Masucci G, Melero I, Mihm M, Palmieri G, Parmiani G, Puzanov I, Romero P, Schilling B, Seliger B, Stroncek D, Taube J, Tomei S, Zarour HM, Testori A, Wang E, Galon J, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. J Transl Med. 2015 Nov 30; 13:374. PMID: 26619946; PMCID: PMC4665874.
  40. Wang Y, Wang X, Ferrone CR, Schwab JH, Ferrone S. Intracellular antigens as targets for antibody based immunotherapy of malignant diseases. Mol Oncol. 2015 Dec; 9(10):1982-93. PMID: 26597109.
    View in: PubMed
  41. Chang CC, Pirozzi G, Wen SH, Chung IH, Chiu BL, Errico S, Luongo M, Lombardi ML, Ferrone S. Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem. 2015 Oct 30; 290(44):26562-75. PMID: 26381407; PMCID: PMC4646314 [Available on 10/30/16].
  42. Sabbatino F, Villani V, Yearley JH, Deshpande V, Cai L, Konstantinidis IT, Moon C, Nota S, Wang Y, Al-Sukaini A, Zhu AX, Goyal L, Ting DT, Bardeesy N, Hong TS, Fernandez-del Castillo C, Tanabe KK, Lillemoe KD, Ferrone S, Ferrone CR. PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016 Jan 15; 22(2):470-8. PMID: 26373575.
    View in: PubMed
  43. Wang Y, Geldres C, Ferrone S, Dotti G. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors. Expert Opin Ther Targets. 2015; 19(10):1339-50. PMID: 26190756.
    View in: PubMed
  44. Srivastava RM, Trivedi S, Concha-Benavente F, Hyun-Bae J, Wang L, Seethala RR, Branstetter BF, Ferrone S, Ferris RL. STAT1-Induced HLA Class I Upregulation Enhances Immunogenicity and Clinical Response to Anti-EGFR mAb Cetuximab Therapy in HNC Patients. Cancer Immunol Res. 2015 Aug; 3(8):936-45. PMID: 25972070; PMCID: PMC4526378.
  45. Tsao CY, Sabbatino F, Cheung NK, Hsu JC, Villani V, Wang X, Ferrone S. Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells. Oncoimmunology. 2015 08; 4(8):e1023975. PMID: 26405581.
    View in: PubMed
  46. Jie HB, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, Whiteside TL, Ferris RL. CTLA-4? Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis. Cancer Res. 2015 Jun 01; 75(11):2200-10. PMID: 25832655; PMCID: PMC4452385.
  47. Ruiz C, Li J, Luttgen MS, Kolatkar A, Kendall JT, Flores E, Topp Z, Samlowski WE, McClay E, Bethel K, Ferrone S, Hicks J, Kuhn P. Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol. 2015 Jan 09; 12(1):016008. PMID: 25574741; PMCID: PMC5023009.
  48. Fenton M, Whiteside TL, Ferrone S, Boyiadzis M. Chondroitin sulfate proteoglycan-4 (CSPG4)-specific monoclonal antibody 225.28 in detection of acute myeloid leukemia blasts. Oncol Res. 2015; 22(2):117-21. PMID: 25706398.
    View in: PubMed
  49. Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E. Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat Commun. 2014 Dec 04; 5:5639. PMID: 25472612; PMCID: PMC4338526.
  50. Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, von Knebel Doeberitz M, Kloor M. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother. 2015 Mar; 64(3):357-66. PMID: 25445815.
    View in: PubMed
  51. Ascierto PA, Grimaldi AM, Anderson AC, Bifulco C, Cochran A, Garbe C, Eggermont AM, Faries M, Ferrone S, Gershenwald JE, Gajewski TF, Halaban R, Hodi FS, Kefford R, Kirkwood JM, Larkin J, Leachman S, Maio M, Marais R, Masucci G, Melero I, Palmieri G, Puzanov I, Ribas A, Saenger Y, Schilling B, Seliger B, Stroncek D, Sullivan R, Testori A, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med. 2014 Oct 28; 12:277. PMID: 25348889; PMCID: PMC4232645.
  52. Sucker A, Zhao F, Real B, Heeke C, Bielefeld N, Maßen S, Horn S, Moll I, Maltaner R, Horn PA, Schilling B, Sabbatino F, Lennerz V, Kloor M, Ferrone S, Schadendorf D, Falk CS, Griewank K, Paschen A. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res. 2014 Dec 15; 20(24):6593-604. PMID: 25294904.
    View in: PubMed
  53. Ferrone S. Therapeutic monoclonal antibodies: introduction. Semin Oncol. 2014 Oct; 41(5):556-8. PMID: 25440602.
    View in: PubMed
  54. Sabbatino F, Fusciello C, Somma D, Pacelli R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Della Vittoria Scarpati G, Ferrone S, Pepe S. Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation. Cytometry A. 2014 Nov; 85(11):953-61. PMID: 25182801.
    View in: PubMed
  55. Beard RE, Zheng Z, Lagisetty KH, Burns WR, Tran E, Hewitt SM, Abate-Daga D, Rosati SF, Fine HA, Ferrone S, Rosenberg SA, Morgan RA. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells. J Immunother Cancer. 2014; 2:25. PMID: 25197555; PMCID: PMC4155770.
  56. Sabbatino F, Wang Y, Wang X, Schwab JH, Ferrone S, Ferrone CR. Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Semin Oncol. 2014 Oct; 41(5):685-99. PMID: 25440613.
    View in: PubMed
  57. Sconocchia G, Eppenberger S, Spagnoli GC, Tornillo L, Droeser R, Caratelli S, Ferrelli F, Coppola A, Arriga R, Lauro D, Iezzi G, Terracciano L, Ferrone S. NK cells and T cells cooperate during the clinical course of colorectal cancer. Oncoimmunology. 2014; 3(8):e952197. PMID: 25610741.
    View in: PubMed
  58. Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, Liu X, Qi Y, Huang P, Lee H, Taghian A, Li JJ, DeLeo AB, Ferrone S, Epperly MW, Ferrone CR, Ly A, Brachtel EF, Wang X. Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget. 2014 Jun 15; 5(11):3743-55. PMID: 25003837; PMCID: PMC4116517.
  59. Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M, De Maria R, Gattino F, Lanzardo S, Lardone E, Martano M, Morello E, Prestigio S, Fiore A, Quaglino E, Zabarino S, Ferrone S, Buracco P, Cavallo F. CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res. 2014 Jul 15; 20(14):3753-62. PMID: 24874834.
    View in: PubMed
  60. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X, Wang Y, Mankin H, Hornicek FJ, Duan Z. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014 Jul; 2(7):690-698. PMID: 24866169; PMCID: PMC4082476.
  61. Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014 Apr 15; 5(7):1926-41. PMID: 24732172; PMCID: PMC4039118.
  62. Leone P, Di Tacchio M, Berardi S, Santantonio T, Fasano M, Ferrone S, Vacca A, Dammacco F, Racanelli V. Dendritic cell maturation in HCV infection: altered regulation of MHC class I antigen processing-presenting machinery. J Hepatol. 2014 Aug; 61(2):242-51. PMID: 24732300.
    View in: PubMed
  63. Morandi F, Di Carlo E, Ferrone S, Petretto A, Pistoia V, Airoldi I. IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol. 2014 Mar 15; 192(6):2634-42. PMID: 24554774.
    View in: PubMed
  64. Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 2014; 7:203-9. PMID: 24570590; PMCID: PMC3933725.
  65. Gameiro SR, Jammeh ML, Wattenberg MM, Tsang KY, Ferrone S, Hodge JW. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014 Jan 30; 5(2):403-16. PMID: 24480782; PMCID: PMC3964216.
  66. Sconocchia G, Eppenberger-Castori S, Zlobec I, Karamitopoulou E, Arriga R, Coppola A, Caratelli S, Spagnoli GC, Lauro D, Lugli A, Han J, Iezzi G, Ferrone C, Ferlosio A, Tornillo L, Droeser R, Rossi P, Attanasio A, Ferrone S, Terracciano L. HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker. Neoplasia. 2014 Jan; 16(1):31-42. PMID: 24563618; PMCID: PMC3924546.
  67. Wang Y, Sabbatino F, Wang X, Ferrone S. Detection of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma. Methods Mol Biol. 2014; 1102:523-35. PMID: 24258997.
    View in: PubMed
  68. Geldres C, Savoldo B, Hoyos V, Caruana I, Zhang M, Yvon E, Del Vecchio M, Creighton CJ, Ittmann M, Ferrone S, Dotti G. T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. Clin Cancer Res. 2014 Feb 15; 20(4):962-71. PMID: 24334762; PMCID: PMC3944408.
  69. Concha-Benavente F, Srivastava RM, Ferrone S, Ferris RL. EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3. Oncoimmunology. 2013 Dec 01; 2(12):e27215. PMID: 24501692.
    View in: PubMed
  70. Volonté A, Di Tomaso T, Spinelli M, Todaro M, Sanvito F, Albarello L, Bissolati M, Ghirardelli L, Orsenigo E, Ferrone S, Doglioni C, Stassi G, Dellabona P, Staudacher C, Parmiani G, Maccalli C. Cancer-initiating cells from colorectal cancer patients escape from T cell-mediated immunosurveillance in vitro through membrane-bound IL-4. J Immunol. 2014 Jan 01; 192(1):523-32. PMID: 24277698.
    View in: PubMed
  71. Fauci JM, Sabbatino F, Wang Y, Londoño-Joshi AI, Straughn JM, Landen CN, Ferrone S, Buchsbaum DJ. Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol. 2014 Jan; 132(1):203-10. PMID: 24216048.
    View in: PubMed
  72. Sabbatino F, Wang Y, Wang X, Ferrone S, Ferrone CR. Emerging BRAF inhibitors for melanoma. Expert Opin Emerg Drugs. 2013 Dec; 18(4):431-43. PMID: 24073999.
    View in: PubMed
  73. Morandi B, Bonaccorsi I, Mesiti M, Conte R, Carrega P, Costa G, Iemmo R, Martini S, Ferrone S, Cantoni C, Mingari MC, Moretta L, Ferlazzo G. Characterization of human afferent lymph dendritic cells from seroma fluids. J Immunol. 2013 Nov 01; 191(9):4858-66. PMID: 24078697.
    View in: PubMed
  74. Scarpati GD, Fusciello C, Sabbatino F, Ferrone S, Caponigro F, Perri F, Carlomagno C, Pepe S. Multidisciplinary approach to patient with malignant melanoma. Anticancer Agents Med Chem. 2013 Jul 01; 13(6):887-900. PMID: 23272971.
    View in: PubMed
  75. Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M. Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med. 2013 Jun 03; 11:137. PMID: 23731854; PMCID: PMC3681569.
  76. Hamilton R, Krauze M, Romkes M, Omolo B, Konstantinopoulos P, Reinhart T, Harasymczuk M, Wang Y, Lin Y, Ferrone S, Whiteside T, Bortoluzzi S, Werley J, Nukui T, Fallert-Junecko B, Kondziolka D, Ibrahim J, Becker D, Kirkwood J, Moschos S. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer. 2013 Aug 01; 119(15):2737-46. PMID: 23695963; PMCID: PMC3901051.
  77. Eisenberg G, Uzana R, Pato A, Frankenburg S, Merims S, Yefenof E, Ferrone S, Peretz T, Machlenkin A, Lotem M. Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive T cells. J Immunol. 2013 Jun 01; 190(11):5856-65. PMID: 23626012; PMCID: PMC3698316.
  78. Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, Gameiro SR. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013 Aug 01; 133(3):624-36. PMID: 23364915.
    View in: PubMed
  79. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, López-Albaitero A, Gibson SP, Gooding WE, Ferrone S, Ferris RL. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013 Apr 01; 19(7):1858-72. PMID: 23444227; PMCID: PMC3640274.
  80. Yeung JT, Hamilton RL, Ohnishi K, Ikeura M, Potter DM, Nikiforova MN, Ferrone S, Jakacki RI, Pollack IF, Okada H. LOH in the HLA class I region at 6p21 is associated with shorter survival in newly diagnosed adult glioblastoma. Clin Cancer Res. 2013 Apr 01; 19(7):1816-26. PMID: 23401227; PMCID: PMC3618546.
  81. Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS One. 2013; 8(2):e47234. PMID: 23408925; PMCID: PMC3567103.
  82. Leibowitz MS, Srivastava RM, Andrade Filho PA, Egloff AM, Wang L, Seethala RR, Ferrone S, Ferris RL. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res. 2013 Feb 15; 19(4):798-808. PMID: 23363816; PMCID: PMC3578140.
  83. Loustau M, Wiendl H, Ferrone S, Carosella ED. HLA-G 2012 conference: the 15-year milestone update. Tissue Antigens. 2013 Mar; 81(3):127-36. PMID: 23347068.
    View in: PubMed
  84. Sabbatino F, Ferrone S. Can the "right" EGFR-specific mAb dramatically improve EGFR-targeted therapy? Clin Cancer Res. 2013 Mar 01; 19(5):958-60. PMID: 23340298.
    View in: PubMed
  85. Sabbatino F, Schwab JH, Ferrone S, Ferrone CR. Evolution of studies of HLA class I antigen processing machinery (APM) components in malignant cells. Clin Transpl. 2013; 453-63. PMID: 25095541.
    View in: PubMed
  86. Whiteside TL, Ferrone S. IGKC and prognosis in breast cancer--response to Schmidt. Clin Cancer Res. 2013 Jan 01; 19(1):305. PMID: 23231949.
    View in: PubMed
  87. Ferrone S. A tribute to Edgardo Carosella on the occasion of the 6th International Conference on HLA-G held in Paris, France, July 9-11, 2012. Hum Immunol. 2013 Apr; 74(4):405. PMID: 23232062.
    View in: PubMed
  88. Wastowski IJ, Simões RT, Yaghi L, Donadi EA, Pancoto JT, Poras I, Lechapt-Zalcman E, Bernaudin M, Valable S, Carlotti CG, Flajollet S, Jensen SS, Ferrone S, Carosella ED, Kristensen BW, Moreau P. Human leukocyte antigen-G is frequently expressed in glioblastoma and may be induced in vitro by combined 5-aza-2'-deoxycytidine and interferon-? treatments: results from a multicentric study. Am J Pathol. 2013 Feb; 182(2):540-52. PMID: 23219427; PMCID: PMC3562737.
  89. Sconocchia G, Arriga R, Tornillo L, Terracciano L, Ferrone S, Spagnoli GC. Melanoma cells inhibit NK cell functions. Cancer Res. 2012 Oct 15; 72(20):5428-9; author reply 5430. PMID: 23047870.
    View in: PubMed
  90. Fauci JM, Straughn JM, Ferrone S, Buchsbaum DJ. A review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer. Gynecol Oncol. 2012 Nov; 127(2):420-5. PMID: 22910694.
    View in: PubMed
  91. Rivera Z, Ferrone S, Wang X, Jube S, Yang H, Pass HI, Kanodia S, Gaudino G, Carbone M. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. Clin Cancer Res. 2012 Oct 01; 18(19):5352-63. PMID: 22893632; PMCID: PMC3463742.
  92. Ascierto PA, Grimaldi AM, Curti B, Faries MB, Ferrone S, Flaherty K, Fox BA, Gajewski TF, Gershenwald JE, Gogas H, Grossmann K, Hauschild A, Hodi FS, Kefford R, Kirkwood JM, Leachmann S, Maio M, Marais R, Palmieri G, Morton DL, Ribas A, Stroncek DF, Stewart R, Wang E, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83. PMID: 22551296; PMCID: PMC3390271.
  93. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012 Sep-Oct; 62(5):309-35. PMID: 22576456; PMCID: PMC3445708.
  94. Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A. Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways. Clin Cancer Res. 2012 Jun 15; 18(12):3316-27. PMID: 22553342; PMCID: PMC3426233.
  95. Campoli M, Fitzpatrick JE, High W, Ferrone S. HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes? J Am Acad Dermatol. 2012 Jun; 66(6):911-6, 916.e1-8. PMID: 22445792.
    View in: PubMed
  96. Whiteside TL, Ferrone S. For breast cancer prognosis, immunoglobulin kappa chain surfaces to the top. Clin Cancer Res. 2012 May 01; 18(9):2417-9. PMID: 22442060; PMCID: PMC3426232.
  97. Favole A, Cascio P, Cerruti F, Sereno A, Tursi M, Tomatis A, Della Beffa C, Ferrone S, Bollo E. MHC class I-related antigen-processing machinery component defects in feline mammary carcinoma. Transl Oncol. 2012 Feb; 5(1):48-55. PMID: 22348176; PMCID: PMC3281407.
  98. Sakaizawa K, Goto Y, Kiniwa Y, Uchiyama A, Harada K, Shimada S, Saida T, Ferrone S, Takata M, Uhara H, Okuyama R. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer. 2012 Feb 28; 106(5):939-46. PMID: 22281663; PMCID: PMC3305957.
  99. Andersson E, Villabona L, Bergfeldt K, Carlson JW, Ferrone S, Kiessling R, Seliger B, Masucci GV. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer. Cancer Immunol Immunother. 2012 Aug; 61(8):1243-53. PMID: 22258792.
    View in: PubMed
  100. Price MA, Colvin Wanshura LE, Yang J, Carlson J, Xiang B, Li G, Ferrone S, Dudek AZ, Turley EA, McCarthy JB. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma. Pigment Cell Melanoma Res. 2011 Dec; 24(6):1148-57. PMID: 22004131; PMCID: PMC3426219.
  101. Tanaka K, Tsuchikawa T, Miyamoto M, Maki T, Ichinokawa M, Kubota KC, Shichinohe T, Hirano S, Ferrone S, Dosaka-Akita H, Matsuno Y, Kondo S. Down-regulation of Human Leukocyte Antigen class I heavy chain in tumors is associated with a poor prognosis in advanced esophageal cancer patients. Int J Oncol. 2012 Apr; 40(4):965-74. PMID: 22134332; PMCID: PMC3584652.
  102. Khoury T, Ademuyiwa FO, Chandrasekhar R, Chandraseekhar R, Jabbour M, Deleo A, Ferrone S, Wang Y, Wang X. Aldehyde dehydrogenase 1A1 expression in breast cancer is associated with stage, triple negativity, and outcome to neoadjuvant chemotherapy. Mod Pathol. 2012 Mar; 25(3):388-97. PMID: 22080062; PMCID: PMC3426278.
  103. Liu Y, Komohara Y, Domenick N, Ohno M, Ikeura M, Hamilton RL, Horbinski C, Wang X, Ferrone S, Okada H. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunol Immunother. 2012 Jun; 61(6):789-801. PMID: 22065046; PMCID: PMC3365630.
  104. Wang X, Katayama A, Wang Y, Yu L, Favoino E, Sakakura K, Favole A, Tsuchikawa T, Silver S, Watkins SC, Kageshita T, Ferrone S. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4. Cancer Res. 2011 Dec 15; 71(24):7410-22. PMID: 22021902; PMCID: PMC3487169.
  105. Ferrone S. Hidden immunotherapy targets challenge dogma. Sci Transl Med. 2011 Sep 07; 3(99):99ps38. PMID: 21900591; PMCID: PMC3426280.
  106. Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, Brand RE, Ferrone CR, Whiteside TL, Ferrone S, DeLeo AB, Wang X. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8? T cells. Clin Cancer Res. 2011 Oct 01; 17(19):6174-84. PMID: 21856769; PMCID: PMC3186874.
  107. Lee SC, Srivastava RM, López-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011 Aug; 50(2-3):248-54. PMID: 21717064; PMCID: PMC3415245.
  108. Morandi F, Corrias MV, Levreri I, Scaruffi P, Raffaghello L, Carlini B, Bocca P, Prigione I, Stigliani S, Amoroso L, Ferrone S, Pistoia V. Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunol Immunother. 2011 Oct; 60(10):1485-95. PMID: 21660451; PMCID: PMC3426043.
  109. Cooney CA, Jousheghany F, Yao-Borengasser A, Phanavanh B, Gomes T, Kieber-Emmons AM, Siegel ER, Suva LJ, Ferrone S, Kieber-Emmons T, Monzavi-Karbassi B. Chondroitin sulfates play a major role in breast cancer metastasis: a role for CSPG4 and CHST11 gene expression in forming surface P-selectin ligands in aggressive breast cancer cells. Breast Cancer Res. 2011 Jun 09; 13(3):R58. PMID: 21658254; PMCID: PMC3218947.
  110. Zarour HM, Ferrone S. Cancer immunotherapy: Progress and challenges in the clinical setting. Eur J Immunol. 2011 Jun; 41(6):1510-5. PMID: 21618503; PMCID: PMC3426035.
  111. Latzka J, Gaier S, Hofstetter G, Balazs N, Smole U, Ferrone S, Scheiner O, Breiteneder H, Pehamberger H, Wagner S. Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One. 2011 May 06; 6(5):e19383. PMID: 21573118; PMCID: PMC3089623.
  112. Campoli M, Ferrone S. HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol. 2011 Jul; 33(4):321-34. PMID: 21523560; PMCID: PMC3426281.
  113. Mayayo SL, Prestigio S, Maniscalco L, La Rosa G, Aricò A, De Maria R, Cavallo F, Ferrone S, Buracco P, Iussich S. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J. 2011 Nov; 190(2):e26-30. PMID: 21482159.
    View in: PubMed
  114. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32. PMID: 21439082; PMCID: PMC3078100.
  115. Chikamatsu K, Takahashi G, Sakakura K, Ferrone S, Masuyama K. Immunoregulatory properties of CD44+ cancer stem-like cells in squamous cell carcinoma of the head and neck. Head Neck. 2011 Feb; 33(2):208-15. PMID: 20848440; PMCID: PMC3426231.
  116. Respa A, Bukur J, Ferrone S, Pawelec G, Zhao Y, Wang E, Marincola FM, Seliger B. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res. 2011 May 01; 17(9):2668-78. PMID: 21248298; PMCID: PMC3426200.
  117. Leibowitz MS, Andrade Filho PA, Ferrone S, Ferris RL. Deficiency of activated STAT1 in head and neck cancer cells mediates TAP1-dependent escape from cytotoxic T lymphocytes. Cancer Immunol Immunother. 2011 Apr; 60(4):525-35. PMID: 21207025; PMCID: PMC3426276.
  118. Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci. 2011 Feb; 68(3):417-31. PMID: 21063893; PMCID: PMC3426238.
  119. Sconocchia G, Zlobec I, Lugli A, Calabrese D, Iezzi G, Karamitopoulou E, Patsouris ES, Peros G, Horcic M, Tornillo L, Zuber M, Droeser R, Muraro MG, Mengus C, Oertli D, Ferrone S, Terracciano L, Spagnoli GC. Tumor infiltration by Fc?RIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma. Int J Cancer. 2011 Jun 01; 128(11):2663-72. PMID: 20715106; PMCID: PMC3426287.
  120. Brady MT, Lee J, Ferrone S, Wang ES, Wetzler M. Interferon-? secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. Leuk Res. 2011 Feb; 35(2):275-7. PMID: 20943267; PMCID: PMC3021772.
  121. Sharafinski ME, Ferris RL, Ferrone S, Grandis JR. Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck. 2010 Oct; 32(10):1412-21. PMID: 20848399; PMCID: PMC2946515.
  122. Wang X, Osada T, Wang Y, Yu L, Sakakura K, Katayama A, McCarthy JB, Brufsky A, Chivukula M, Khoury T, Hsu DS, Barry WT, Lyerly HK, Clay TM, Ferrone S. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst. 2010 Oct 06; 102(19):1496-512. PMID: 20852124; PMCID: PMC2950168.
  123. Michel S, Linnebacher M, Alcaniz J, Voss M, Wagner R, Dippold W, Becker C, von Knebel Doeberitz M, Ferrone S, Kloor M. Lack of HLA class II antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class II regulatory genes. Int J Cancer. 2010 Aug 15; 127(4):889-98. PMID: 20013806; PMCID: PMC2892639.
  124. Ferris RL, Jaffee EM, Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010 Oct 01; 28(28):4390-9. PMID: 20697078; PMCID: PMC2954137.
  125. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, Ferrone CR, Favoino E, Koya Y, Campoli MR, McCarthy JB, DeLeo AB, Ferrone S. CSPG4 in cancer: multiple roles. Curr Mol Med. 2010 Jun; 10(4):419-29. PMID: 20455858.
    View in: PubMed
  126. Mine T, Matsueda S, Gao H, Li Y, Wong KK, Peoples GE, Ferrone S, Ioannides CG. Created Gli-1 duplex short-RNA (i-Gli-RNA) eliminates CD44 Hi progenitors of taxol-resistant ovarian cancer cells. Oncol Rep. 2010 Jun; 23(6):1537-43. PMID: 20428807; PMCID: PMC3426036.
  127. Burns WR, Zhao Y, Frankel TL, Hinrichs CS, Zheng Z, Xu H, Feldman SA, Ferrone S, Rosenberg SA, Morgan RA. A high molecular weight melanoma-associated antigen-specific chimeric antigen receptor redirects lymphocytes to target human melanomas. Cancer Res. 2010 Apr 15; 70(8):3027-33. PMID: 20395199.
    View in: PubMed
  128. Cairo MS, Jordan CT, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralt SA, June CH. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant. 2010 Jun; 16(6):709-28. PMID: 20227509; PMCID: PMC3711411.
  129. Di Tomaso T, Mazzoleni S, Wang E, Sovena G, Clavenna D, Franzin A, Mortini P, Ferrone S, Doglioni C, Marincola FM, Galli R, Parmiani G, Maccalli C. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res. 2010 Feb 01; 16(3):800-13. PMID: 20103663; PMCID: PMC2842003.
  130. Karyampudi L, Formicola C, Erskine CL, Maurer MJ, Ingle JN, Krco CJ, Wettstein PJ, Kalli KR, Fikes JD, Beebe M, Hartmann LC, Disis ML, Ferrone S, Ishioka G, Knutson KL. A degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102. Clin Cancer Res. 2010 Feb 01; 16(3):825-34. PMID: 20103660; PMCID: PMC2818599.
  131. Meyer Zu Horste G, Heidenreich H, Lehmann HC, Ferrone S, Hartung HP, Wiendl H, Kieseier BC. Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies. Glia. 2010 Jan 01; 58(1):80-92. PMID: 19544394; PMCID: PMC3480724.
  132. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res. 2010; 109:73-121. PMID: 21070915.
    View in: PubMed
  133. Campoli M, Ferris R, Ferrone S, Wang X. Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res. 2010 Jan 01; 16(1):11-20. PMID: 20028761; PMCID: PMC2802861.
  134. Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F. Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood. 2010 Feb 11; 115(6):1185-93. PMID: 20008301; PMCID: PMC2826230.
  135. Seliger B, Stoehr R, Handke D, Mueller A, Ferrone S, Wullich B, Tannapfel A, Hofstaedter F, Hartmann A. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol Immunother. 2010 Apr; 59(4):529-40. PMID: 19820934; PMCID: PMC3426221.
  136. Cathro HP, Smolkin ME, Theodorescu D, Jo VY, Ferrone S, Frierson HF. Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother. 2010 Mar; 59(3):465-72. PMID: 19756593; PMCID: PMC3426234.
  137. Lin J, Takata M, Murata H, Goto Y, Kido K, Ferrone S, Saida T. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst. 2009 Oct 21; 101(20):1423-7. PMID: 19752400; PMCID: PMC2765260.
  138. Yang J, Price MA, Li GY, Bar-Eli M, Salgia R, Jagedeeswaran R, Carlson JH, Ferrone S, Turley EA, McCarthy JB. Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res. 2009 Oct 01; 69(19):7538-47. PMID: 19738072; PMCID: PMC2762355.
  139. Sconocchia G, Spagnoli GC, Del Principe D, Ferrone S, Anselmi M, Wongsena W, Cervelli V, Schultz-Thater E, Wyler S, Carafa V, Moch H, Terracciano L, Tornillo L. Defective infiltration of natural killer cells in MICA/B-positive renal cell carcinoma involves beta(2)-integrin-mediated interaction. Neoplasia. 2009 Jul; 11(7):662-71. PMID: 19568411; PMCID: PMC2697352.
  140. López-Albaitero A, Mailliard R, Hackman T, Andrade Filho PA, Wang X, Gooding W, Ferrone S, Kalinski P, Ferris RL. Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function. J Immunother. 2009 Jun; 32(5):465-73. PMID: 19609238; PMCID: PMC2913548.
  141. Shen Y, Xia M, Zhang J, Xu L, Yang J, Chen A, Miao F, Ferrone S, Xie W. IRF-1 and p65 mediate upregulation of constitutive HLA-A antigen expression by hepatocellular carcinoma cells. Mol Immunol. 2009 Jun; 46(10):2045-53. PMID: 19428110; PMCID: PMC3426235.
  142. Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol. 2009 May 01; 182(9):5240-9. PMID: 19380770; PMCID: PMC3426222.
  143. La Rocca R, Fulciniti M, Lakshmikanth T, Mesuraca M, Ali TH, Mazzei V, Amodio N, Catalano L, Rotoli B, Ouerfelli O, Grieco M, Gulletta E, Bond HM, Morrone G, Ferrone S, Carbone E. Early hematopoietic zinc finger protein prevents tumor cell recognition by natural killer cells. J Immunol. 2009 Apr 15; 182(8):4529-37. PMID: 19342626; PMCID: PMC2747523.
  144. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Höglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Kärre K, Shibuya A, Carbone E, Colucci F. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest. 2009 May; 119(5):1251-63. PMID: 19349689; PMCID: PMC2673866.
  145. López-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. 2009 Nov; 58(11):1853-64. PMID: 19319529; PMCID: PMC3426289.
  146. Weiner LM, Dhodapkar MV, Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet. 2009 Mar 21; 373(9668):1033-40. PMID: 19304016; PMCID: PMC2677705.
  147. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH, Radisky DC, Ferrone S, Knutson KL. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009 Apr 01; 69(7):2887-95. PMID: 19276366; PMCID: PMC2664865.
  148. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, Morton DL, Ferrone S, Hoon DS. mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem. 2009 Apr; 55(4):757-64. PMID: 19233913; PMCID: PMC2760934.
  149. Paul AK, Ciesielski MJ, Sajjad M, Wang X, Ferrone S, Abdel-Nabi H, Fenstermaker RA. Expression of HMP/AN2, a melanoma associated antigen, in murine cerebral gliomas: potential for radioimmunotargeting. J Neurooncol. 2009 Aug; 94(1):21-30. PMID: 19152070; PMCID: PMC2741310.
  150. Tosello V, Zamarchi R, Merlo A, Gorza M, Piovan E, Mandruzzato S, Bronte V, Wang X, Ferrone S, Amadori A, Zanovello P. Differential expression of constitutive and inducible proteasome subunits in human monocyte-derived DC differentiated in the presence of IFN-alpha or IL-4. Eur J Immunol. 2009 Jan; 39(1):56-66. PMID: 19065646; PMCID: PMC2747509.
  151. Mine T, Matsueda S, Li Y, Tokumitsu H, Gao H, Danes C, Wong KK, Wang X, Ferrone S, Ioannides CG. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother. 2009 Aug; 58(8):1185-94. PMID: 19048252; PMCID: PMC2726795.
  152. Seliger B, Marincola FM, Ferrone S, Abken H. The complex role of B7 molecules in tumor immunology. Trends Mol Med. 2008 Dec; 14(12):550-9. PMID: 18986838; PMCID: PMC2726789.
  153. Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS. Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther. 2008 Nov; 7(11):3642-53. PMID: 19001446; PMCID: PMC3480738.
  154. Wongsena W, Sconocchia G, Cho HS, Chang CC, Wang X, Klumkrathok K, Ferrone S, Leelayuwat C. Production and characterization of monoclonal antibodies against major histocompatibility complex class I chain-related gene A. Tissue Antigens. 2008 Nov; 72(5):431-40. PMID: 18937790; PMCID: PMC3426284.
  155. Verheyden S, Ferrone S, Mulder A, Claas FH, Schots R, De Moerloose B, Benoit Y, Demanet C. Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells. Cancer Immunol Immunother. 2009 Jun; 58(6):855-65. PMID: 18841361; PMCID: PMC3426282.
  156. Campoli M, Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene. 2008 Oct 06; 27(45):5869-85. PMID: 18836468; PMCID: PMC2729106.
  157. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res. 2008 Oct 01; 68(19):8066-75. PMID: 18829565; PMCID: PMC3004011.
  158. Tourkova IL, Shurin GV, Ferrone S, Shurin MR. Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunol Immunother. 2009 Apr; 58(4):567-74. PMID: 18751977; PMCID: PMC4006356.
  159. Hsieh CH, Hsu YJ, Chang CC, Liu HC, Chuang KL, Chuang CK, Pang ST, Hasumi K, Ferrone S, Liao SK. Total HLA class I loss in a sarcomatoid renal carcinoma cell line caused by the coexistence of distinct mutations in the two encoding beta2-microglobulin genes. Cancer Immunol Immunother. 2009 Mar; 58(3):395-408. PMID: 18704411; PMCID: PMC2793116.
  160. Campoli M, Ferrone S. Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens. 2008 Oct; 72(4):321-34. PMID: 18700879; PMCID: PMC2729103.
  161. Drake AS, Brady MT, Wang XH, Sait SJ, Earp JC, Ghoshal Gupta S, Ferrone S, Wang ES, Wetzler M. Targeting 11q23 positive acute leukemia cells with high molecular weight-melanoma associated antigen-specific monoclonal antibodies. Cancer Immunol Immunother. 2009 Mar; 58(3):415-27. PMID: 18677475; PMCID: PMC2741306.
  162. Schwab JH, Boland PJ, Agaram NP, Socci ND, Guo T, O'Toole GC, Wang X, Ostroumov E, Hunter CJ, Block JA, Doty S, Ferrone S, Healey JH, Antonescu CR. Chordoma and chondrosarcoma gene profile: implications for immunotherapy. Cancer Immunol Immunother. 2009 Mar; 58(3):339-49. PMID: 18641983; PMCID: PMC3426285.
  163. Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, Herlyn D. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice. Cancer Immunol Immunother. 2008 Jul; 57(7):1079-89. PMID: 18157673; PMCID: PMC3426288.
  164. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK. HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res. 2008 Jun 01; 14(11):3372-9. PMID: 18519766; PMCID: PMC3426216.
  165. Goto Y, Ferrone S, Arigami T, Kitago M, Tanemura A, Sunami E, Nguyen SL, Turner RR, Morton DL, Hoon DS. Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res. 2008 Jun 01; 14(11):3401-7. PMID: 18519770; PMCID: PMC2686117.
  166. Andersson E, Johansson CC, Villabona L, Kanter L, Helgadottir H, Dalianis T, Bergfeldt K, Seliger B, Ferrone S, Kiessling R, Masucci GV. Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level. J Clin Oncol. 2008 May 20; 26(15_suppl):16544. PMID: 27948841.
    View in: PubMed
  167. Vujanovic L, Whiteside TL, Potter DM, Chu J, Ferrone S, Butterfield LH. Regulation of antigen presentation machinery in human dendritic cells by recombinant adenovirus. Cancer Immunol Immunother. 2009 Jan; 58(1):121-33. PMID: 18488218; PMCID: PMC2726804.
  168. Schwenkert M, Birkholz K, Schwemmlein M, Kellner C, Kügler M, Peipp M, Nettelbeck DM, Schuler-Thurner B, Schaft N, Dörrie J, Ferrone S, Kämpgen E, Fey GH. A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. Melanoma Res. 2008 Apr; 18(2):73-84. PMID: 18337643; PMCID: PMC2741307.
  169. Morandi F, Raffaghello L, Bianchi G, Meloni F, Salis A, Millo E, Ferrone S, Barnaba V, Pistoia V. Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens. Stem Cells. 2008 May; 26(5):1275-87. PMID: 18292209; PMCID: PMC2726787.
  170. Belicha-Villanueva A, McEvoy S, Cycon K, Ferrone S, Gollnick SO, Bangia N. Differential contribution of TAP and tapasin to HLA class I antigen expression. Immunology. 2008 May; 124(1):112-20. PMID: 18194274; PMCID: PMC2434385.
  171. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am. 2007 Oct; 16(4):755-74, viii. PMID: 18022543.
    View in: PubMed
  172. Signorino E, Brusa D, Granata R, Malavasi F, Ferrone S, Matera L. Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies. Cancer Biol Ther. 2007 Dec; 6(12):1932-7. PMID: 18087220.
    View in: PubMed
  173. Tsuda N, Chang DZ, Mine T, Efferson C, García-Sastre A, Wang X, Ferrone S, Ioannides CG. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res. 2007 Sep 01; 67(17):8378-87. PMID: 17804754.
    View in: PubMed
  174. Connolly N, Riddler S, Stanson J, Gooding W, Rinaldo CR, Ferrone S, Whiteside TL. Levels of antigen processing machinery components in dendritic cells generated for vaccination of HIV-1+ subjects. AIDS. 2007 Aug 20; 21(13):1683-92. PMID: 17690565.
    View in: PubMed
  175. Ko E, Luo W, Peng L, Wang X, Ferrone S. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity. Cancer Res. 2007 Aug 15; 67(16):7875-84. PMID: 17699794.
    View in: PubMed
  176. Pistoia V, Morandi F, Wang X, Ferrone S. Soluble HLA-G: Are they clinically relevant? Semin Cancer Biol. 2007 Dec; 17(6):469-79. PMID: 17825579; PMCID: PMC2200630.
  177. Mehta AM, Jordanova ES, Kenter GG, Ferrone S, Fleuren GJ. Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. Cancer Immunol Immunother. 2008 Feb; 57(2):197-206. PMID: 17622526; PMCID: PMC2082063.
  178. Morandi F, Levreri I, Bocca P, Galleni B, Raffaghello L, Ferrone S, Prigione I, Pistoia V. Human neuroblastoma cells trigger an immunosuppressive program in monocytes by stimulating soluble HLA-G release. Cancer Res. 2007 Jul 01; 67(13):6433-41. PMID: 17616704.
    View in: PubMed
  179. Oflazoglu E, Elliott M, Takita H, Ferrone S, Henderson RA, Repasky EA. Adoptively transferred human lung tumor specific cytotoxic T cells can control autologous tumor growth and shape tumor phenotype in a SCID mouse xenograft model. J Transl Med. 2007 Jun 25; 5:29. PMID: 17592641; PMCID: PMC1933531.
  180. Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garrè ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res. 2007 Jun 01; 67(11):5471-8. PMID: 17545629.
    View in: PubMed
  181. Ogino T, Moriai S, Ishida Y, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer. 2007 Jun 01; 120(11):2401-10. PMID: 17315195.
    View in: PubMed
  182. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H. WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol. 2007 Aug; 114(2):111-9. PMID: 17541610.
    View in: PubMed
  183. Theurillat JP, Zürrer-Härdi U, Varga Z, Storz M, Probst-Hensch NM, Seifert B, Fehr MK, Fink D, Ferrone S, Pestalozzi B, Jungbluth AA, Chen YT, Jäger D, Knuth A, Moch H. NY-BR-1 protein expression in breast carcinoma: a mammary gland differentiation antigen as target for cancer immunotherapy. Cancer Immunol Immunother. 2007 Nov; 56(11):1723-31. PMID: 17410359.
    View in: PubMed
  184. Vermeulen CF, Jordanova ES, ter Haar NT, Kolkman-Uljee SM, de Miranda NF, Ferrone S, Peters AA, Fleuren GJ. Expression and genetic analysis of transporter associated with antigen processing in cervical carcinoma. Gynecol Oncol. 2007 Jun; 105(3):593-9. PMID: 17382375.
    View in: PubMed
  185. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, Kirkwood JM. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31. PMID: 17332298.
    View in: PubMed
  186. Dierssen JW, de Miranda NF, Ferrone S, van Puijenbroek M, Cornelisse CJ, Fleuren GJ, van Wezel T, Morreau H. HNPCC versus sporadic microsatellite-unstable colon cancers follow different routes toward loss of HLA class I expression. BMC Cancer. 2007 Feb 22; 7:33. PMID: 17316446; PMCID: PMC1808468.
  187. Almeciga I, Wang ZC, Zúñiga J, Fernandez-Viña M, Clavijo O, Araujo H, Romero V, Henry J, Ferrone S, Yunis EJ. Allorecognition of an HLA-A*01 aberrant allele by an HLA identical family member carrying the HLA-A*0101 allele. J Immunol. 2006 Dec 15; 177(12):8643-9. PMID: 17142764.
    View in: PubMed
  188. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006 Sep 15; 66(18):9281-9. PMID: 16982773.
    View in: PubMed
  189. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res. 2006 Sep 15; 12(18):5503-10. PMID: 17000686.
    View in: PubMed
  190. Leys CM, Nomura S, LaFleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR. Expression and prognostic significance of prothymosin-alpha and ERp57 in human gastric cancer. Surgery. 2007 Jan; 141(1):41-50. PMID: 17188166.
    View in: PubMed
  191. Chang CC, Ferrone S. NK cell activating ligands on human malignant cells: molecular and functional defects and potential clinical relevance. Semin Cancer Biol. 2006 Oct; 16(5):383-92. PMID: 16931041.
    View in: PubMed
  192. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006 Jul 01; 12(13):3890-5. PMID: 16818683.
    View in: PubMed
  193. Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer. 2006 Jul 01; 119(1):157-61. PMID: 16450373.
    View in: PubMed
  194. Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res. 2006 Jul 01; 66(13):6503-11. PMID: 16818621.
    View in: PubMed
  195. Chang CC, Ferrone S. Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother. 2007 Feb; 56(2):227-36. PMID: 16783578.
    View in: PubMed
  196. Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S. Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients. Cancer Res. 2006 Jun 15; 66(12):6405-11. PMID: 16778219.
    View in: PubMed
  197. Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J Immunol. 2006 May 15; 176(10):6046-54. PMID: 16670313.
    View in: PubMed
  198. Luo W, Wang X, Kageshita T, Wakasugi S, Karpf AR, Ferrone S. Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells. Oncogene. 2006 May 11; 25(20):2873-84. PMID: 16407841.
    View in: PubMed
  199. Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL, Ferrone S. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem. 2006 Jul 07; 281(27):18763-73. PMID: 16648140.
    View in: PubMed
  200. Slingluff CL, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2342s-2345s. PMID: 16609056.
    View in: PubMed
  201. López-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006 Mar 15; 176(6):3402-9. PMID: 16517708.
    View in: PubMed
  202. Peng L, Ko E, Luo W, Wang X, Shrikant PA, Ferrone S. CD4-dependent potentiation of a high molecular weight-melanoma-associated antigen-specific CTL response elicited in HLA-A2/Kb transgenic mice. J Immunol. 2006 Feb 15; 176(4):2307-15. PMID: 16455987.
    View in: PubMed
  203. Bangia N, Ferrone S. Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes? Immunol Invest. 2006; 35(3-4):485-503. PMID: 16916763.
    View in: PubMed
  204. Seliger B, Ritz U, Ferrone S. Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation. Int J Cancer. 2006 Jan 01; 118(1):129-38. PMID: 16003759.
    View in: PubMed
  205. Facoetti A, Nano R, Zelini P, Morbini P, Benericetti E, Ceroni M, Campoli M, Ferrone S. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin Cancer Res. 2005 Dec 01; 11(23):8304-11. PMID: 16322289.
    View in: PubMed
  206. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res. 2005 Dec 01; 65(23):11146-55. PMID: 16322265.
    View in: PubMed
  207. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res. 2005 Nov 15; 65(22):10139-44. PMID: 16287995.
    View in: PubMed
  208. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Morandi F, Bocca P, Gambini C, Ferrone S, Pistoia V. Mechanisms of immune evasion of human neuroblastoma. Cancer Lett. 2005 Oct 18; 228(1-2):155-61. PMID: 15923080.
    View in: PubMed
  209. Chang CC, Hernandez-Guzman FG, Luo W, Wang X, Ferrone S, Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem. 2005 Dec 16; 280(50):41546-52. PMID: 16227204.
    View in: PubMed
  210. Ramnath N, Tan D, Li Q, Hylander BL, Bogner P, Ryes L, Ferrone S. Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother. 2006 Aug; 55(8):891-9. PMID: 16187081.
    View in: PubMed
  211. Tourkova IL, Shurin GV, Chatta GS, Perez L, Finke J, Whiteside TL, Ferrone S, Shurin MR. Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol. 2005 Sep 01; 175(5):3045-52. PMID: 16116192.
    View in: PubMed
  212. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens. 2005 Sep; 66(3):185-94. PMID: 16101829.
    View in: PubMed
  213. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol. 2005 Sep; 125(3):526-31. PMID: 16117794.
    View in: PubMed
  214. Wang X, Ko EC, Peng L, Gillies SD, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: enhancement of immunogenicity of anti-idiotypic monoclonal antibody MK2-23 by fusion with interleukin 2. Cancer Res. 2005 Aug 01; 65(15):6976-83. PMID: 16061683.
    View in: PubMed
  215. Sconocchia G, Lau M, Provenzano M, Rezvani K, Wongsena W, Fujiwara H, Hensel N, Melenhorst J, Li J, Ferrone S, Barrett AJ. The antileukemia effect of HLA-matched NK and NK-T cells in chronic myelogenous leukemia involves NKG2D-target-cell interactions. Blood. 2005 Nov 15; 106(10):3666-72. PMID: 16046526; PMCID: PMC1895055.
  216. Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, von Knebel Doeberitz M. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 2005 Jul 15; 65(14):6418-24. PMID: 16024646.
    View in: PubMed
  217. Kawano K, Ferrone S, Ioannides CG. Functional idiotopes: tumor antigen-directed expression of CD8+ T-cell epitopes nested in unique NH2-terminal VH sequence of antiidiotypic antibodies? Cancer Res. 2005 Jul 15; 65(14):6001-4. PMID: 16024597.
    View in: PubMed
  218. Claus JA, Brady MT, Lee J, Donohue KA, Sait SN, Ferrone S, Wetzler M. T-Cell activation by t(9;22) acute lymphoblastic leukemia-derived dendritic-like cells is associated with increased tapasin expression. Cancer Immunol Immunother. 2006 Feb; 55(2):160-5. PMID: 16010586.
    View in: PubMed
  219. Raffaghello L, Prigione I, Bocca P, Morandi F, Camoriano M, Gambini C, Wang X, Ferrone S, Pistoia V. Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications. Oncogene. 2005 Jul 07; 24(29):4634-44. PMID: 15897905.
    View in: PubMed
  220. Yan WH, Lin AF, Chang CC, Ferrone S. Induction of HLA-G expression in a melanoma cell line OCM-1A following the treatment with 5-aza-2'-deoxycytidine. Cell Res. 2005 Jul; 15(7):523-31. PMID: 16045815.
    View in: PubMed
  221. Luo W, Hsu JC, Tsao CY, Ko E, Wang X, Ferrone S. Differential immunogenicity of two peptides isolated by high molecular weight-melanoma-associated antigen-specific monoclonal antibodies with different affinities. J Immunol. 2005 Jun 01; 174(11):7104-10. PMID: 15905554.
    View in: PubMed
  222. Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol. 2005 Jun 01; 174(11):6863-71. PMID: 15905528.
    View in: PubMed
  223. Padmanabhan S, Bansal H, Hylander B, Baer M, Ferrone S, Repasky E. Differential gene regulation of WT1 protein tumor antigen and the components of the antigen processing machinery by interferon-gamma signaling in myeloid leukemia. J Clin Oncol. 2005 Jun; 23(16_suppl):2587. PMID: 27945882.
    View in: PubMed
  224. Kageshita T, Ishihara T, Campoli M, Ferrone S. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens. 2005 May; 65(5):419-28. PMID: 15853896.
    View in: PubMed
  225. Bolesta E, Kowalczyk A, Wierzbicki A, Rotkiewicz P, Bambach B, Tsao CY, Horwacik I, Kolinski A, Rokita H, Brecher M, Wang X, Ferrone S, Kozbor D. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 2005 Apr 15; 65(8):3410-8. PMID: 15833876.
    View in: PubMed
  226. Hafner C, Breiteneder H, Ferrone S, Thallinger C, Wagner S, Schmidt WM, Jasinska J, Kundi M, Wolff K, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer. 2005 Apr 10; 114(3):426-32. PMID: 15578703.
    View in: PubMed
  227. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S, Seliger B. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res. 2005 Apr 01; 11(7):2552-60. PMID: 15814633.
    View in: PubMed
  228. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections. J Immunol Methods. 2005 Apr; 299(1-2):139-51. PMID: 15896802.
    View in: PubMed
  229. Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol. 2005 Feb 01; 174(3):1462-71. PMID: 15661905.
    View in: PubMed
  230. Wagner S, Hafner C, Allwardt D, Jasinska J, Ferrone S, Zielinski CC, Scheiner O, Wiedermann U, Pehamberger H, Breiteneder H. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol. 2005 Jan 15; 174(2):976-82. PMID: 15634921.
    View in: PubMed
  231. Ferris RL, Hunt JL, Ferrone S. Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res. 2005; 33(2):113-33. PMID: 16234579.
    View in: PubMed
  232. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res. 2005 Jan 01; 11(1):67-72. PMID: 15671529.
    View in: PubMed
  233. Luo W, Hsu JC, Kieber-Emmons T, Wang X, Ferrone S. Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases. Cancer Chemother Biol Response Modif. 2005; 22:769-87. PMID: 16110640.
    View in: PubMed
  234. Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv Cancer Res. 2005; 93:189-234. PMID: 15797448.
    View in: PubMed
  235. Campoli M, Ferrone S, Zea AH, Rodriguez PC, Ochoa AC. Mechanisms of tumor evasion. Cancer Treat Res. 2005; 123:61-88. PMID: 16211866.
    View in: PubMed
  236. Chang CC, Campoli M, Luo W, Zhao W, Zaenker KS, Ferrone S. Immunotherapy of melanoma targeting human high molecular weight melanoma-associated antigen: potential role of nonimmunological mechanisms. Ann N Y Acad Sci. 2004 Dec; 1028:340-50. PMID: 15650259.
    View in: PubMed
  237. Prigione I, Corrias MV, Airoldi I, Raffaghello L, Morandi F, Bocca P, Cocco C, Ferrone S, Pistoia V. Immunogenicity of human neuroblastoma. Ann N Y Acad Sci. 2004 Dec; 1028:69-80. PMID: 15650233.
    View in: PubMed
  238. Wang X, Campoli M, Ko E, Luo W, Ferrone S. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. J Immunol Methods. 2004 Nov; 294(1-2):23-35. PMID: 15604013.
    View in: PubMed
  239. Chang CC, Campoli M, Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis? Curr Opin Immunol. 2004 Oct; 16(5):644-50. PMID: 15342012.
    View in: PubMed
  240. Ferrone S. Immunotherapy dispenses with tumor antigens. Nat Biotechnol. 2004 Sep; 22(9):1096-8. PMID: 15340476.
    View in: PubMed
  241. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, Pende D, Steinle A, Ferrone S, Pistoia V. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma. Neoplasia. 2004 Sep-Oct; 6(5):558-68. PMID: 15548365; PMCID: PMC1531660.
  242. Whiteside TL, Stanson J, Shurin MR, Ferrone S. Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol. 2004 Aug 01; 173(3):1526-34. PMID: 15265880.
    View in: PubMed
  243. Murray JL, Gillogly M, Kawano K, Efferson CL, Lee JE, Ross M, Wang X, Ferrone S, Ioannides CG. Fine specificity of high molecular weight-melanoma-associated antigen-specific cytotoxic T lymphocytes elicited by anti-idiotypic monoclonal antibodies in patients with melanoma. Cancer Res. 2004 Aug 01; 64(15):5481-8. PMID: 15289358.
    View in: PubMed
  244. Sabbatini P, Aghajanian C, Dupont J, Derosa F, Anderson S, McGuire W, Rodabaugh K, Ferrone S, Lele S, Odunsi K. Phase I trial of the anti-idiotypic monoclonal antibody (mAb) ACA-125 in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5018. PMID: 28015480.
    View in: PubMed
  245. Yang J, Price MA, Neudauer CL, Wilson C, Ferrone S, Xia H, Iida J, Simpson MA, McCarthy JB. Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms. J Cell Biol. 2004 Jun 21; 165(6):881-91. PMID: 15210734; PMCID: PMC2172406.
  246. Mankoff SP, Brander C, Ferrone S, Marincola FM. Lost in Translation: Obstacles to Translational Medicine. J Transl Med. 2004 May 18; 2(1):14. PMID: 15149545.
    View in: PubMed
  247. Campoli M, Ferrone S. T-cell-based immunotherapy of melanoma: what have we learned and how can we improve? Expert Rev Vaccines. 2004 Apr; 3(2):171-87. PMID: 15056043.
    View in: PubMed
  248. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, Seliger B. MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer. 2004 Mar 20; 109(2):265-73. PMID: 14750179.
    View in: PubMed
  249. Atkins D, Ferrone S, Schmahl GE, Störkel S, Seliger B. Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J Urol. 2004 Feb; 171(2 Pt 1):885-9. PMID: 14713847.
    View in: PubMed
  250. Campoli M, Chang CC, Oldford SA, Edgecombe AD, Drover S, Ferrone S. HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis. 2004; 20:105-25. PMID: 15687712.
    View in: PubMed
  251. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit Rev Immunol. 2004; 24(4):267-96. PMID: 15588226.
    View in: PubMed
  252. Demanet C, Mulder A, Deneys V, Worsham MJ, Maes P, Claas FH, Ferrone S. Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: an escape mechanism from CTL and NK attack? Blood. 2004 Apr 15; 103(8):3122-30. PMID: 15070694.
    View in: PubMed
  253. Chang CC, Campoli M, Ferrone S. HLA class I defects in malignant lesions: what have we learned? Keio J Med. 2003 Dec; 52(4):220-9. PMID: 14748474.
    View in: PubMed
  254. Marincola FM, Ferrone S. Immunotherapy of melanoma: the good news, the bad ones and what to do next. Semin Cancer Biol. 2003 Dec; 13(6):387-9. PMID: 15001156.
    View in: PubMed
  255. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Challenges and strategies. Int Arch Allergy Immunol. 2003 Dec; 132(4):294-309. PMID: 14707461.
    View in: PubMed
  256. Chang CC, Murphy SP, Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol. 2003 Nov; 64(11):1057-63. PMID: 14602236.
    View in: PubMed
  257. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S. Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens. 2003 Nov; 62(5):385-93. PMID: 14617045.
    View in: PubMed
  258. Chang CC, Ferrone S. HLA-G in melanoma: can the current controversies be solved? Semin Cancer Biol. 2003 Oct; 13(5):361-9. PMID: 14708716.
    View in: PubMed
  259. Ogino T, Bandoh N, Hayashi T, Miyokawa N, Harabuchi Y, Ferrone S. Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients. Clin Cancer Res. 2003 Sep 15; 9(11):4043-51. PMID: 14519625.
    View in: PubMed
  260. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide. J Immunol. 2003 Aug 15; 171(4):1918-26. PMID: 12902494.
    View in: PubMed
  261. Dissemond J, Goette P, Moers J, Lindeke A, Goos M, Ferrone S, Wagner SN. Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions: association with lack of spontaneous regression. Melanoma Res. 2003 Aug; 13(4):371-7. PMID: 12883363.
    View in: PubMed
  262. Wang X, Liang B, Rebmann V, Lu J, Celis E, Kageshita T, Grosse-Wilde H, Ferrone S. Specificity and functional characteristics of anti-HLA-A mAbs LGIII-147.4.1 and LGIII-220.6.2. Tissue Antigens. 2003 Aug; 62(2):139-48. PMID: 12889994.
    View in: PubMed
  263. Ogino T, Wang X, Ferrone S. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods. 2003 Jul; 278(1-2):33-44. PMID: 12957394.
    View in: PubMed
  264. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol. 2003 Jun; 24(6):335-42. PMID: 12810110.
    View in: PubMed
  265. Dissemond J, Götte P, Mörs J, Lindeke A, Goos M, Ferrone S, Wagner SN. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003 Jun; 13(3):253-8. PMID: 12777979.
    View in: PubMed
  266. Seliger B, Atkins D, Bock M, Ritz U, Ferrone S, Huber C, Störkel S. Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. Clin Cancer Res. 2003 May; 9(5):1721-7. PMID: 12738726.
    View in: PubMed
  267. Weinman EC, Roche PC, Kasperbauer JL, Cha SS, Sargent DJ, Cheville J, Murphy LM, Chen L, Wettstein PJ, Gostout B, Ferrone S, Strome SE. Characterization of antigen processing machinery and Survivin expression in tonsillar squamous cell carcinoma. Cancer. 2003 May 01; 97(9):2203-11. PMID: 12712472.
    View in: PubMed
  268. Wetzler M, McElwain BK, Stewart CC, Blumenson L, Mortazavi A, Ford LA, Slack JL, Barcos M, Ferrone S, Baer MR. HLA-DR antigen-negative acute myeloid leukemia. Leukemia. 2003 Apr; 17(4):707-15. PMID: 12682628.
    View in: PubMed
  269. Yang T, McNally BA, Ferrone S, Liu Y, Zheng P. A single-nucleotide deletion leads to rapid degradation of TAP-1 mRNA in a melanoma cell line. J Biol Chem. 2003 Apr 25; 278(17):15291-6. PMID: 12582163.
    View in: PubMed
  270. Seliger B, Abken H, Ferrone S. HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol. 2003 Feb; 24(2):82-7. PMID: 12547505.
    View in: PubMed
  271. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol. 2003 Jan; 33(1):125-34. PMID: 12594841.
    View in: PubMed
  272. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune selection. Vaccine. 2002 Dec 19; 20 Suppl 4:A40-5. PMID: 12477427.
    View in: PubMed
  273. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002 Nov 01; 62(21):6178-86. PMID: 12414645.
    View in: PubMed
  274. Ferrone S. Changes in serum ganglioside and antibody levels in soft tissue sarcoma: are they the cause or the effect of tumor progression? Cancer J. 2002 Sep-Oct; 8(5):369-70. PMID: 12416893.
    View in: PubMed
  275. Wang ZC, Smith AG, Yunis EJ, Selvakumar A, Ferrone S, McKinney S, Lee JH, Fernandez-Vina M, Hansen JA. Molecular characterization of the HLA-Cw*0409N allele. Hum Immunol. 2002 Apr; 63(4):295-300. PMID: 12039411.
    View in: PubMed
  276. Seliger B, Cabrera T, Garrido F, Ferrone S. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002 Feb; 12(1):3-13. PMID: 11926409.
    View in: PubMed
  277. Noronha EJ, Wang X, Ferrone S. Isolation of human tumor-associated cell surface antigen-binding scFvs. Methods Mol Biol. 2002; 178:227-33. PMID: 11968492.
    View in: PubMed
  278. Rothenfusser S, Buchwald A, Kock S, Ferrone S, Fisch P. Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes. Cell Immunol. 2002 Jan; 215(1):32-44. PMID: 12142034.
    View in: PubMed
  279. Seliger B, Ritz U, Abele R, Bock M, Tampé R, Sutter G, Drexler I, Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res. 2001 Dec 15; 61(24):8647-50. PMID: 11751378.
    View in: PubMed
  280. Ericsson C, Seregard S, Bartolazzi A, Levitskaya E, Ferrone S, Kiessling R, Larsson O. Association of HLA class I and class II antigen expression and mortality in uveal melanoma. Invest Ophthalmol Vis Sci. 2001 Sep; 42(10):2153-6. PMID: 11527924.
    View in: PubMed
  281. Ugurel S, Rebmann V, Ferrone S, Tilgen W, Grosse-Wilde H, Reinhold U. Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001 Jul 15; 92(2):369-76. PMID: 11466692.
    View in: PubMed
  282. Herlyn M, Ferrone S, Ronai Z, Finerty J, Pelroy R, Mohla S. Melanoma biology and progression. Cancer Res. 2001 Jun 01; 61(11):4642-3. PMID: 11389102.
    View in: PubMed
  283. Kamarashev J, Ferrone S, Seifert B, Böni R, Nestle FO, Burg G, Dummer R. TAP1 down-regulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer. 2001 Jan 20; 95(1):23-8. PMID: 11241306.
    View in: PubMed
  284. Ferrone S, Wang X. Active specific immunotherapy of malignant melanoma and peptide mimics of the human high-molecular-weight melanoma-associated antigen. Recent Results Cancer Res. 2001; 158:231-5. PMID: 11092050.
    View in: PubMed
  285. Wang X, Luo W, Foon KA, Ferrone S. Tumor associated antigen (TAA) mimicry and immunotherapy of malignant diseases from anti-idiotypic antibodies to peptide mimics. Cancer Chemother Biol Response Modif. 2001; 19:309-26. PMID: 11686020.
    View in: PubMed
  286. Wetzler M, Baer MR, Stewart SJ, Donohue K, Ford L, Stewart CC, Repasky EA, Ferrone S. HLA class I antigen cell surface expression is preserved on acute myeloid leukemia blasts at diagnosis and at relapse. Leukemia. 2001 Jan; 15(1):128-33. PMID: 11243380.
    View in: PubMed
  287. Paul P, Rouas-Freiss N, Moreau P, Cabestre FA, Menier C, Khalil-Daher I, Pangault C, Onno M, Fauchet R, Martinez-Laso J, Morales P, Villena AA, Giacomini P, Natali PG, Frumento G, Ferrara GB, McMaster M, Fisher S, Schust D, Ferrone S, Dausset J, Geraghty D, Carosella ED. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol. 2000 Nov; 61(11):1177-95. PMID: 11137224.
    View in: PubMed
  288. Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H, Moy FJ, Powers R, Ferrone S. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol. 2000 Sep 15; 165(6):3275-83. PMID: 10975844.
    View in: PubMed
  289. Kiessling R, Pawelec G, Welsh RM, Barry JD, Ferrone S. Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies. Mol Med Today. 2000 Sep; 6(9):344-6. PMID: 11202973.
    View in: PubMed
  290. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000 Sep; 21(9):455-64. PMID: 10953098.
    View in: PubMed
  291. Moy FJ, Desai SA, Wang X, Noronha EJ, Zhou Q, Ferrone S, Powers R. Analysis by NMR spectroscopy of the structural homology between the linear and the cyclic peptide recognized by anti-human leukocyte antigen class I monoclonal antibody TP25.99*. J Biol Chem. 2000 Aug 11; 275(32):24679-85. PMID: 10825172.
    View in: PubMed
  292. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother. 2000 Aug; 49(6):314-8. PMID: 10946813.
    View in: PubMed
  293. Puppo F, Brenci S, Contini P, Bignardi D, Hamby CV, Filaci G, Ghio M, Scudeletti M, Picciotto A, Indiveri F, Ferrone S. Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. Tissue Antigens. 2000 Apr; 55(4):333-41. PMID: 10852385.
    View in: PubMed
  294. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Differential clinical significance of alpha(v)Beta(3) expression in primary lesions of acral lentiginous melanoma and of other melanoma histotypes. Int J Cancer. 2000 Mar 20; 89(2):153-9. PMID: 10754493.
    View in: PubMed
  295. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol. 2000 Feb; 12(2):195-203. PMID: 10653855.
    View in: PubMed
  296. Ferrone S, Finerty JF, Jaffee EM, Nabel GJ. How much longer will tumour cells fool the immune system? Immunol Today. 2000 Feb; 21(2):70-2. PMID: 10712001.
    View in: PubMed
  297. Wang X, Luo W, Ferrone S. Immunotherapy of melanoma: peptide mimics of a human high molecular weight-melanoma associated antigen. Medicina (B Aires). 2000; 60 Suppl 2:48-50. PMID: 11188931.
    View in: PubMed
  298. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol. 2000; 74:181-273. PMID: 10605607.
    View in: PubMed
  299. Perosa F, Prete M, Luccarelli G, Favoino B, Ferrone S, Dammacco F. Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. Hum Immunol. 1999 Nov; 60(11):1058-66. PMID: 10600003.
    View in: PubMed
  300. Perosa F, Luccarelli G, Prete M, Ferrone S, Dammacco F. Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. Br J Haematol. 1999 Sep; 106(4):987-94. PMID: 10520002.
    View in: PubMed
  301. Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S. Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med. 1999 Jul 19; 190(2):205-15. PMID: 10432284; PMCID: PMC2195569.
  302. Reinhold U, Liu L, Lüdtke-Handjery HC, Heuser C, Hombach A, Wang X, Tilgen W, Ferrone S, Abken H. Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J Invest Dermatol. 1999 May; 112(5):744-50. PMID: 10233766.
    View in: PubMed
  303. Finke J, Ferrone S, Frey A, Mufson A, Ochoa A. Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today. 1999 Apr; 20(4):158-60. PMID: 10203710.
    View in: PubMed
  304. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today. 1999 Apr; 5(4):178-86. PMID: 10203751.
    View in: PubMed
  305. Cormier JN, Panelli MC, Hackett JA, Bettinotti MP, Mixon A, Wunderlich J, Parker LL, Restifo NP, Ferrone S, Marincola FM. Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer. 1999 Mar 01; 80(5):781-90. PMID: 10048982.
    View in: PubMed
  306. Puppo F, Bignardi D, Contini P, Hamby CV, Brenci S, Lanza L, Ghio M, Scudeletti M, Indiveri F, Ferrone S. Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-micro-associated HLA class I heavy chain levels and HLA phenotype. Tissue Antigens. 1999 Mar; 53(3):253-62. PMID: 10203018.
    View in: PubMed
  307. Kageshita T, Hirai S, Ono T, Hicklin DJ, Ferrone S. Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol. 1999 Mar; 154(3):745-54. PMID: 10079252; PMCID: PMC1866429.
  308. Willers J, Lucchese A, Kanduc D, Ferrone S. Molecular mimicry of phage displayed peptides mimicking GD3 ganglioside. Peptides. 1999; 20(9):1021-6. PMID: 10499418.
    View in: PubMed
  309. Rebmann V, Pfeiffer K, Pässler M, Ferrone S, Maier S, Weiss E, Grosse-Wilde H. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens. 1999 Jan; 53(1):14-22. PMID: 10082427.
    View in: PubMed
  310. Burlingham WJ, Jankowska-Gan E, DeVito-Haynes L, Fechner JH, Hogan KT, Claas FH, Mulder A, Wang X, Ferrone S. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. J Immunol. 1998 Dec 15; 161(12):6705-14. PMID: 9862700.
    View in: PubMed
  311. Hamby CV, Chinol M, Palestro CJ, Manzo C, Ferrone S. Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23. Int J Cancer. 1998 Nov 09; 78(4):486-90. PMID: 9797138.
    View in: PubMed
  312. Noronha EJ, Wang X, Desai SA, Kageshita T, Ferrone S. Limited diversity of human scFv fragments isolated by panning a synthetic phage-display scFv library with cultured human melanoma cells. J Immunol. 1998 Sep 15; 161(6):2968-76. PMID: 9743360.
    View in: PubMed
  313. Fayen J, Huang JH, Ferrone S, Tykocinski ML. Negative signaling by anti-HLA class I antibodies is dependent upon two triggering events. Int Immunol. 1998 Sep; 10(9):1347-58. PMID: 9786434.
    View in: PubMed
  314. Wang Z, Arienti F, Parmiani G, Ferrone S. Induction and functional characterization of beta2-microglobulin (beta2-mu)-free HLA class I heavy chains expressed by beta2-mu-deficient human FO-1 melanoma cells. Eur J Immunol. 1998 Sep; 28(9):2817-26. PMID: 9754569.
    View in: PubMed
  315. Bresciani A, Pirozzi G, Spera M, Lombardi ML, Ambrosone L, Migliaresi S, Ferrone S, Manzo C. Increased level of serum HLA class I antigens in patients with systemic lupus in patients with systemic lupus erythematosus. Correlation with disease activity. Tissue Antigens. 1998 Jul; 52(1):44-50. PMID: 9714473.
    View in: PubMed
  316. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. Different requirements for signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem. 1998 Jun 26; 273(26):16177-83. PMID: 9632673.
    View in: PubMed
  317. Hicklin DJ, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S. beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998 Jun 15; 101(12):2720-9. PMID: 9637706; PMCID: PMC508863.
  318. Desai SA, Wang X, Noronha EJ, Kageshita T, Ferrone S. Characterization of human anti-high molecular weight-melanoma-associated antigen single-chain Fv fragments isolated from a phage display antibody library. Cancer Res. 1998 Jun 01; 58(11):2417-25. PMID: 9622083.
    View in: PubMed
  319. Wang Z, Seliger B, Mike N, Momburg F, Knuth A, Ferrone S. Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. Cancer Res. 1998 May 15; 58(10):2149-57. PMID: 9605759.
    View in: PubMed
  320. Völk H, Charlemagne J, Tournefier A, Ferrone S, Jost R, Parisot R, Kaufman J. Wide tissue distribution of axolotl class II molecules occurs independently of thyroxin. Immunogenetics. 1998 Apr; 47(5):339-49. PMID: 9510551.
    View in: PubMed
  321. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998 Feb 15; 58(4):737-42. PMID: 9485029.
    View in: PubMed
  322. Kishore R, Hicklin DJ, Dellaratta DV, Golde U, Kageshita T, Seliger B, Ferrone S. Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. Tissue Antigens. 1998 Feb; 51(2):129-40. PMID: 9510369.
    View in: PubMed
  323. Abken H, Hombach A, Reinhold U, Ferrone S. Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells? Immunol Today. 1998 Jan; 19(1):2-5. PMID: 9465480.
    View in: PubMed
  324. Perosa F, Luccarelli G, Neri M, De Pinto V, Ferrone S, Dammacco F. Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile. Int J Clin Lab Res. 1998; 28(4):246-51. PMID: 9879499.
    View in: PubMed
  325. Fisch P, Meuer E, Pende D, Rothenfusser S, Viale O, Kock S, Ferrone S, Fradelizi D, Klein G, Moretta L, Rammensee HG, Boon T, Coulie P, van der Bruggen P. Control of B cell lymphoma recognition via natural killer inhibitory receptors implies a role for human Vgamma9/Vdelta2 T cells in tumor immunity. Eur J Immunol. 1997 Dec; 27(12):3368-79. PMID: 9464825.
    View in: PubMed
  326. Dellaratta DV, Hicklin DJ, Kishore R, Kageshita T, Ferrone S. Characterization of rabbit antisera elicited with human LMP2- and LMP7-specific peptides and recombinant proteins. Tissue Antigens. 1997 Dec; 50(6):567-75. PMID: 9458109.
    View in: PubMed
  327. Zhu X, Bavari S, Ulrich R, Sadegh-Nasseri S, Ferrone S, McHugh L, Mage M. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Eur J Immunol. 1997 Aug; 27(8):1933-41. PMID: 9295029.
    View in: PubMed
  328. Hicklin DJ, Dellaratta DV, Kishore R, Liang B, Kageshita T, Ferrone S. Beta2-microglobulin gene mutations in human melanoma cells: molecular characterization and implications for immune surveillance. Melanoma Res. 1997 Aug; 7 Suppl 2:S67-74. PMID: 9578419.
    View in: PubMed
  329. Turco MC, Romano MF, Lamberti A, Petrella A, Bisogni R, Sun SC, Ferrone S, Bonelli P, Cerra M, Venuta S. Induction of nuclear factor kappa B/Rel nuclear activity in human peripheral blood T lymphocytes by anti-HLA class I monoclonal antibodies. Tissue Antigens. 1997 Jul; 50(1):1-7. PMID: 9243748.
    View in: PubMed
  330. Mutz M, Hawthorne T, Ferrone S, Pluschke G. Titration calorimetry study of an anti-idiotypic antibody cascade in a human melanoma-associated antigen system. Mol Immunol. 1997 Jul; 34(10):695-707. PMID: 9430197.
    View in: PubMed
  331. Seliger B, Maeurer MJ, Ferrone S. TAP off--tumors on. Immunol Today. 1997 Jun; 18(6):292-9. PMID: 9190116.
    View in: PubMed
  332. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F, Giannarelli D, Temponi M, Ferrone S. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res. 1997 Apr 15; 57(8):1554-60. PMID: 9108459.
    View in: PubMed
  333. Puppo F, Indiveri F, Scudeletti M, Ferrone S. Soluble HLA antigens: new roles and uses. Immunol Today. 1997 Apr; 18(4):154-5. PMID: 9136450.
    View in: PubMed
  334. Hamby CV, Chinol M, Manzo C, Ferrone S. Purification by affinity chromatography with anti-idiotypic monoclonal antibodies of immunoreactive monoclonal antibodies following labeling with 188Re. Hybridoma. 1997 Feb; 16(1):27-31. PMID: 9085125.
    View in: PubMed
  335. Reisfeld RA, Ferrone S. International Conference on the Biology of Melanoma. Aviano, Italy, 24-26 September 1995. Melanoma Res. 1996 Dec; 6(6):447-56. PMID: 9013483.
    View in: PubMed
  336. Merimsky O, Shoenfeld Y, Baharav E, Altomonte M, Chaitchik S, Maio M, Ferrone S, Fishman P. Melanoma-associated hypopigmentation: where are the antibodies? Am J Clin Oncol. 1996 Dec; 19(6):613-8. PMID: 8931683.
    View in: PubMed
  337. Hicklin DJ, Kageshita T, Ferrone S. Development and characterization of rabbit antisera to human MHC-linked transporters associated with antigen processing. Tissue Antigens. 1996 Jul; 48(1):38-46. PMID: 8864173.
    View in: PubMed
  338. Boccaletti V, Temponi M, Wang Z, Manganoni AM, Marcelli M, Maio M, Ferrone S, De Panfilis G. The vitronectin receptor alpha-V beta-3, contrary to ICAM-1, is not modulated by interferon-gamma and tumour necrosis factor-alpha on melanoma cell lines. Acta Derm Venereol. 1996 Jul; 76(4):269-73. PMID: 8869681.
    View in: PubMed
  339. Wang Z, Margulies L, Hicklin DJ, Ferrone S. Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens. 1996 May; 47(5):382-90. PMID: 8795138.
    View in: PubMed
  340. Puppo F, Brenci S, Ghio M, Bignardi D, Contini P, Bacigalupo A, Van Lint MT, Scudeletti M, Ferrone S, Indiveri F. Serum HLA class I antigen levels in allogeneic bone marrow transplantation: a possible marker of acute GVHD. Bone Marrow Transplant. 1996 May; 17(5):753-8. PMID: 8733693.
    View in: PubMed
  341. Ferrone S. Anti-idiotypic monoclonal antibodies as therapeutic vaccines. Melanoma Res. 1996 Apr; 6(2):179. PMID: 8791277.
    View in: PubMed
  342. Ban N, Day J, Wang X, Ferrone S, McPherson A. Crystal structure of an anti-anti-idiotype shows it to be self-complementary. J Mol Biol. 1996 Feb 02; 255(4):617-27. PMID: 8568901.
    View in: PubMed
  343. Baharav E, Merimsky O, Altomonte M, Shoenfeld Y, Pavlovic M, Maio M, Ferrone S, Fishman P. Anti-tyrosinase antibodies participate in the immune response to vaccination with anti-idiotypic antibodies mimicking the high-molecular-weight melanoma-associated antigen. Melanoma Res. 1995 Oct; 5(5):337-43. PMID: 8541724.
    View in: PubMed
  344. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995 Oct; 16(10):487-94. PMID: 7576053.
    View in: PubMed
  345. Arkin S, Ferrone S, Lipton JM. Modulation of adhesion molecule CD54 expression on CD34+ hematopoietic progenitors. Exp Hematol. 1995 Jul; 23(7):588-96. PMID: 7541368.
    View in: PubMed
  346. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res. 1995 Jul; 1(7):705-13. PMID: 9816036.
    View in: PubMed
  347. Mittelman A, Wang X, Matsumoto K, Ferrone S. Antiantiidiotypic response and clinical course of the disease in patients with malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Hybridoma. 1995 Apr; 14(2):175-81. PMID: 7590776.
    View in: PubMed
  348. Puppo F, Scudeletti M, Indiveri F, Ferrone S. Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today. 1995 Mar; 16(3):124-7. PMID: 7718084.
    View in: PubMed
  349. Kageshita T, Hirai S, Ono T, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic MAb MK2-23. Immunohistochemical analysis of the reactivity of anti-anti-idiotypic MAb with surgically removed melanoma lesions. Int J Cancer. 1995 Jan 27; 60(3):334-40. PMID: 7829240.
    View in: PubMed
  350. Iwasaki Y, Takabatake H, Monestier M, Ferrone S. Idiotypic diversity and variable region gene usage by mouse anti-HLA-DQ3 mAb. Immunogenetics. 1995; 42(2):90-100. PMID: 7607710.
    View in: PubMed
  351. Shoenfeld Y, Amital H, Ferrone S, Kennedy RC. Anti-idiotypes and their application under autoimmune, neoplastic, and infectious conditions. Int Arch Allergy Immunol. 1994 Nov; 105(3):211-23. PMID: 7920023.
    View in: PubMed
  352. Iwasaki Y, Takabatake H, Shinji T, Monestier M, Ferrone S. Structural profile of idiotype, anti-idiotype and anti-anti-idiotype monoclonal antibodies in the HLA-DQ3 antigenic system. Eur J Immunol. 1994 Nov; 24(11):2874-81. PMID: 7957578.
    View in: PubMed
  353. Castagnoli C, Stella M, Magliacani G, Ferrone S, Richiardi PM. Similar ectopic expression of ICAM-1 and HLA class II molecules in hypertrophic scars following thermal injury. Burns. 1994 Oct; 20(5):430-3. PMID: 7999272.
    View in: PubMed
  354. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res. 1994 Sep 15; 54(18):4848-50. PMID: 8069850.
    View in: PubMed
  355. May LT, Patel K, García D, Ndubuisi MI, Ferrone S, Mittelman A, Mackiewicz A, Sehgal PB. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood. 1994 Sep 15; 84(6):1887-95. PMID: 8080995.
    View in: PubMed
  356. Puppo F, Brenci S, Lanza L, Bosco O, Imro MA, Scudeletti M, Indiveri F, Ferrone S. Increased level of serum HLA class I antigens in HIV infection. Correlation with disease progression. Hum Immunol. 1994 Aug; 40(4):259-66. PMID: 8002375.
    View in: PubMed
  357. Ferrone S. Melanoma, immune surveillance, and immunotherapy. J Clin Invest. 1994 Apr; 93(4):1351-2. PMID: 8163637; PMCID: PMC294144.
  358. Takamiya Y, Schönbach C, Nokihara K, Yamaguchi M, Ferrone S, Kano K, Egawa K, Takiguchi M. HLA-B*3501-peptide interactions: role of anchor residues of peptides in their binding to HLA-B*3501 molecules. Int Immunol. 1994 Feb; 6(2):255-61. PMID: 8155602.
    View in: PubMed
  359. Kageshita T, Kimura T, Yoshi A, Hirai S, Ono T, Ferrone S. Antigenic profile of mucosal melanoma lesions. Int J Cancer. 1994 Feb 01; 56(3):370-4. PMID: 8314324.
    View in: PubMed
  360. Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23. Cancer Res. 1994 Jan 15; 54(2):415-21. PMID: 8275478.
    View in: PubMed
  361. Gattoni-Celli S, Byers RH, Calorini L, Ferrone S. Organ-specific metastases in melanoma: experimental animal models. Pigment Cell Res. 1993 Dec; 6(6):381-4. PMID: 8146087.
    View in: PubMed
  362. Di Rosa F, D'Oro U, Ruggiero G, Racioppi L, Acquaviva A, Ferrone S, Fontana S, Zappacosta S. HLA class II molecules transduce accessory signals affecting the CD3 but not the interleukin-2 activation pathway in T blasts. Hum Immunol. 1993 Dec; 38(4):251-60. PMID: 8138420.
    View in: PubMed
  363. Kageshita T, Yoshii A, Kimura T, Kuriya N, Ono T, Tsujisaki M, Imai K, Ferrone S. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma. Cancer Res. 1993 Oct 15; 53(20):4927-32. PMID: 8104688.
    View in: PubMed
  364. Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yecheskel G, Ferrone S, Zigelman R, Chaitchik S, Floro S, Djaldetti M. Vitiligo autoantibodies are effective against melanoma. Cancer. 1993 Oct 15; 72(8):2365-9. PMID: 8402450.
    View in: PubMed
  365. Ferrone S. Anti-idiotypes in melanoma. Hybridoma. 1993 Oct; 12(5):509-14. PMID: 8300123.
    View in: PubMed
  366. Wang Z, Hu XZ, Tatake RJ, Yang SY, Zeff RA, Ferrone S. Differential effect of human and mouse beta 2-microglobulin on the induction and the antigenic profile of endogenous HLA-A and -B antigens synthesized by beta 2-microglobulin gene-null FO-1 melanoma cells. Cancer Res. 1993 Sep 15; 53(18):4303-9. PMID: 7689931.
    View in: PubMed
  367. Ferrone S, Kageshita T, Hirai S. Active specific immunotherapy of malignant melanoma with anti-idiotypic monoclonal antibodies. J Dermatol. 1993 Sep; 20(9):533-9. PMID: 8227707.
    View in: PubMed
  368. Ferrone S. Human tumor-associated antigen mimicry by anti-idiotypic antibodies. Immunogenicity and clinical trials in patients with solid tumors. Ann N Y Acad Sci. 1993 Aug 12; 690:214-24. PMID: 8368740.
    View in: PubMed
  369. Chen ZJ, Ferrone S. Comparison of the binding parameters to melanoma cells of antihuman high molecular weight-melanoma associated antigen (HMW-MAA) monoclonal antibodies (mAb) and syngeneic anti-anti-idiotypic (anti-anti-id) mAb. Ann N Y Acad Sci. 1993 Aug 12; 690:398-401. PMID: 8368768.
    View in: PubMed
  370. Gattoni-Celli S, Calorini L, Simile MM, Ferrone S. Modulation by MHC class I antigens of the biology of melanoma cells. Non-immunological mechanisms. Melanoma Res. 1993 Aug; 3(4):285-9. PMID: 8219762.
    View in: PubMed
  371. Tedesco F, Narchi G, Radillo O, Meri S, Ferrone S, Betterle C. Susceptibility of human trophoblast to killing by human complement and the role of the complement regulatory proteins. J Immunol. 1993 Aug 01; 151(3):1562-70. PMID: 7687635.
    View in: PubMed
  372. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, Gattoni-Celli S, Ferrone S. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res. 1993 Jul 15; 53(14):3349-54. PMID: 7686817.
    View in: PubMed
  373. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 1993 Jul 15; 53(14):3343-8. PMID: 7686816.
    View in: PubMed
  374. Pouletty P, Chang C, Kalil J, Atwood E, Ferrone S, Shimizu B, Howson W, Mazaheri R, Del Villano B, Grumet C. Typing of serum-soluble HLA-B27 antigen by ELISA. Tissue Antigens. 1993 Jul; 42(1):14-9. PMID: 8248889.
    View in: PubMed
  375. Pouletty P, Ferrone S, Amesland F, Cohen N, Westhoff U, Charron D, Shimizu RM, Grosse-Wilde H. Summary report from the first international workshop on soluble HLA antigens. Paris, August 1992. Tissue Antigens. 1993 Jul; 42(1):45-54. PMID: 7504328.
    View in: PubMed
  376. Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S. Idiotypic cascade in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. Eur J Immunol. 1993 Jul; 23(7):1671-7. PMID: 7686858.
    View in: PubMed
  377. Yang YM, Rutberg SE, Luo FC, Spratt TE, Halaban R, Ferrone S, Ronai Z. A transcriptional inhibitor induced in human melanoma cells upon ultraviolet irradiation. Cell Growth Differ. 1993 Jul; 4(7):595-602. PMID: 8398900.
    View in: PubMed
  378. Kageshita T, Kuriya N, Ono T, Horikoshi T, Takahashi M, Wong GY, Ferrone S. Association of high molecular weight melanoma-associated antigen expression in primary acral lentiginous melanoma lesions with poor prognosis. Cancer Res. 1993 Jun 15; 53(12):2830-3. PMID: 8504426.
    View in: PubMed
  379. Temponi M, Kekish U, Hamby CV, Nielsen H, Marboe CC, Ferrone S. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. J Immunol Methods. 1993 May 26; 161(2):239-56. PMID: 8505553.
    View in: PubMed
  380. Mariani SM, Armandola EA, Ferrone S. Preferential selection of a subset of anti-HLA-DR monoclonal antibodies by a syngeneic antiidiotypic monoclonal antibody. Transplantation. 1993 May; 55(5):1176-81. PMID: 7684538.
    View in: PubMed
  381. Armandola EA, Mariani SM, Ferrone S. Serological and molecular characterization of mouse anti-idiotypic monoclonal antibodies elicited with the syngeneic anti-HLA-A2,28 monoclonal antibody CR11-351. Mol Immunol. 1993 Feb; 30(3):287-300. PMID: 8433707.
    View in: PubMed
  382. Wang Z, Cao Y, Albino AP, Zeff RA, Houghton A, Ferrone S. Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest. 1993 Feb; 91(2):684-92. PMID: 8432869; PMCID: PMC288010.
  383. Quagliata F, Schenkelaars EJ, Ferrone S. Immunotherapeutic approach to rheumatoid arthritis with anti-idiotypic antibodies to HLA-DR4. Isr J Med Sci. 1993 Feb-Mar; 29(2-3):154-9. PMID: 8468170.
    View in: PubMed
  384. Gattoni-Celli S, Calorini L, Byers HR, Etoh T, Wang Z, Ferrone S. Abnormalities in HLA class I antigen expression by melanoma cells: structural characterization and functional implications. J Invest Dermatol. 1993 Feb; 100(2 Suppl):226S-230S. PMID: 8433012.
    View in: PubMed
  385. Ferrone S, Chen ZJ, Liu CC, Hirai S, Kageshita T, Mittelman A. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibodies MK2-23. Experimental studies and clinical trials in patients with malignant melanoma. Pharmacol Ther. 1993 Feb-Mar; 57(2-3):259-90. PMID: 8361995.
    View in: PubMed
  386. Chen ZJ, Yang H, Liu CC, Hirai S, Ferrone S. Modulation by adjuvants and carriers of the immunogenicity in xenogeneic hosts of mouse anti-idiotypic monoclonal antibody MK2-23, an internal image of human high molecular weight-melanoma associated antigen. Cancer Res. 1993 Jan 01; 53(1):112-9. PMID: 8416734.
    View in: PubMed
  387. Mariani SM, Armandola EA, Ferrone S. Diversity of anti-HLA-DR antibodies elicited by distinct anti-idiotypic monoclonal antibodies recognizing idiotopes co-expressed by the immunizing monoclonal antibody. Immunology. 1992 Dec; 77(4):597-603. PMID: 1283602; PMCID: PMC1421656.
  388. Mariani SM, Armandola EA, Ferrone S. Heterogeneity in the anti-HLA-DR immune response elicited by the antiidiotypic monoclonal antibody F5-444. Analysis at the clonal level. Transplantation. 1992 Dec; 54(6):1078-84. PMID: 1281563.
    View in: PubMed
  389. Armandola EA, Mariani SM, Zwickl M, Hardman N, Ferrone S. Molecular analysis of anti-idiotypic monoclonal antibodies in the HLA-DR antigenic system. Eur J Immunol. 1992 Nov; 22(11):2893-9. PMID: 1425914.
    View in: PubMed
  390. Wang Z, Cao Y, D'Urso CM, Ferrone S. Differential susceptibility of cultured human melanoma cell lines to enhancement by retinoic acid of intercellular adhesion molecule 1 expression. Cancer Res. 1992 Sep 01; 52(17):4766-72. PMID: 1355009.
    View in: PubMed
  391. Tatake RJ, Ferrone S, Zeff RA. The role of beta-2 microglobulin in temperature-sensitive and interferon-gamma-induced exocytosis of HLA class I molecules. Transplantation. 1992 Sep; 54(3):395-403. PMID: 1412716.
    View in: PubMed
  392. Cozzi E, Ferrone S. Immunotherapeutic approaches with monoclonal antibodies to immunological diseases. Recenti Prog Med. 1992 Sep; 83(9):528-33. PMID: 1439123.
    View in: PubMed
  393. Kageshita T, Ono T, Hirai S, Yoshii A, Kimura T, Nakakuma H, Horikawa K, Takatsuki K, Ferrone S. Ganglioside, adhesion molecule, and HLA antigen expression in basal cell carcinoma lesions. Cancer Res. 1992 Jun 01; 52(11):3201-7. PMID: 1350511.
    View in: PubMed
  394. Tanabe M, Sekimata M, Ferrone S, Takiguchi M. Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol. 1992 May 15; 148(10):3202-9. PMID: 1374450.
    View in: PubMed
  395. Temponi M, Gold AM, Ferrone S. Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res. 1992 May 01; 52(9):2497-503. PMID: 1373670.
    View in: PubMed
  396. Sakaguchi K, Koide N, Takenami T, Matsushima H, Takabatake H, Ferrone S, Tsuji T. Soluble HLA class I antigens in sera of patients with chronic hepatitis. Gastroenterol Jpn. 1992 Apr; 27(2):206-11. PMID: 1577226.
    View in: PubMed
  397. Dal Canton A, Fuiano G, Sepe V, Caglioti A, Ferrone S. Mesangial expression of intercellular adhesion molecule-1 in primary glomerulosclerosis. Kidney Int. 1992 Apr; 41(4):951-5. PMID: 1381006.
    View in: PubMed
  398. Matsui M, Yoshimura S, Nakanishi T, Ferrone S. Effect of tumor size on the enhancement by gamma interferon of the localization of radiolabeled F(ab')2 fragments of anti-intercellular adhesion molecule-1 monoclonal antibodies in human colon carcinoma cells grafted in nude mice. Cancer Res. 1992 Mar 01; 52(5):1309-13. PMID: 1346588.
    View in: PubMed
  399. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A. 1992 Jan 15; 89(2):466-70. PMID: 1731316; PMCID: PMC48259.
  400. Kageshita T, Yamada M, Arao T, Ferrone S. Expression of high molecular weight-melanoma associated antigen (HMW-MAA) in primary ALM lesions is associated with a poor prognosis. Pigment Cell Res. 1992; Suppl 2:132-5. PMID: 1409414.
    View in: PubMed
  401. Guarini L, Graham GM, Jiang H, Ferrone S, Zucker S, Fisher PB. Modulation of the antigenic phenotype of human melanoma cells by differentiation-inducing and growth-suppressing agents. Pigment Cell Res. 1992; Suppl 2:123-31. PMID: 1357650.
    View in: PubMed
  402. Chen ZJ, Yang H, Liu CC, Mittelman A, Ferrone S. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma. Pigment Cell Res. 1992; Suppl 2:113-22. PMID: 1409413.
    View in: PubMed
  403. Perosa F, Ferrone S, Dammacco F. Anti-idiotypic monoclonal antibodies reacting with idiotope on isolated-denatured chains of an anti-CD4 monoclonal antibody. Immunology. 1991 Dec; 74(4):748-50. PMID: 1783432; PMCID: PMC1384790.
  404. Chattopadhyay P, Kaveri SV, Byars N, Starkey J, Ferrone S, Raychaudhuri S. Human high molecular weight-melanoma associated antigen mimicry by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1. Cancer Res. 1991 Nov 15; 51(22):6045-51. PMID: 1933867.
    View in: PubMed
  405. Shoenfeld Y, Ferrone S, Bombardieri S. New aspects in the treatment of immunomediated diseases. Clin Exp Rheumatol. 1991 Nov-Dec; 9(6):663-73. PMID: 1684923.
    View in: PubMed
  406. Temponi M, Fawwaz RA, Kekish U, Wang TS, Ferrone S. Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti-HMW-MAA MAb TP61.5 in nude mice bearing human melanoma lesions. Int J Cancer. 1991 Oct 21; 49(4):624-30. PMID: 1917164.
    View in: PubMed
  407. Turco MC, Alfinito F, De Felice M, Lamberti A, Ferrone S, Venuta S. T-cell malignancies with mature phenotypes: altered cell cycle regulation by HLA class I molecules. Blood. 1991 Oct 15; 78(8):2045-52. PMID: 1680497.
    View in: PubMed
  408. Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang HP, Gottesman MM, Ferrone S, Fisher PB. Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells. J Natl Cancer Inst. 1991 Sep 18; 83(18):1307-15. PMID: 1653364.
    View in: PubMed
  409. Chen ZJ, Yang H, Kageshita T, Ferrone S. Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res. 1991 Sep 15; 51(18):4790-7. PMID: 1716513.
    View in: PubMed
  410. Moolenaar W, Bruijn JA, Schrama E, Ferrone S, Daha MR, Zwinderman AH, Hoedemaeker PJ, van Es LA, van der Woude FJ. T-cell receptors and ICAM-1 expression in renal allografts during rejection. Transpl Int. 1991 Sep; 4(3):140-5. PMID: 1958278.
    View in: PubMed
  411. Mariani SM, Armandola EA, Ferrone S. Diversity in the fine specificity and idiotypic profile of mouse anti-HLA-DR monoclonal antibody elicited with the syngeneic anti-idiotypic monoclonal antibody F5-830. J Immunol. 1991 Aug 15; 147(4):1322-30. PMID: 1714480.
    View in: PubMed
  412. Chen ZJ, Yang H, Ferrone S. Human high molecular weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody MK2-23. Characterization of the immunogenicity in syngeneic hosts. J Immunol. 1991 Aug 01; 147(3):1082-90. PMID: 1861071.
    View in: PubMed
  413. Hayashibe K, Mishima Y, Ferrone S. Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma. J Immunol. 1991 Aug 01; 147(3):1098-104. PMID: 1861072.
    View in: PubMed
  414. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest. 1991 Jul; 88(1):282-9. PMID: 1905328; PMCID: PMC296030.
  415. Kageshita T, Nakamura T, Yamada M, Kuriya N, Arao T, Ferrone S. Differential expression of melanoma associated antigens in acral lentiginous melanoma